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INTRODUCTION 
 
 
Physicians have observed the effects of diabetes for thousands of 
years. For much of this time, little was known about this fatal disease that 
caused wasting away of the body, extreme thirst, and frequent urination. It 
wasn't until 1922 that the first patient was successfully treated with insulin. 
One of the effects of diabetes is the presence of glucose in the urine 
(glucosuria). Ancient Hindu writings, many thousands of years old, 
document how black ants and flies were attracted to the urine of diabetics. 
The Indian physician Sushruta in 400 B.C. described the sweet taste of urine 
from affected individuals, and for many centuries to come, the sweet taste of 
urine was key to diagnosis.[38] 
Around 250 B.C., the name “diabetes” was first used. It is a Greek 
word that means “to syphon”, reflecting how diabetes seemed to rapidly 
drain fluid from the affected individual. The Greek physician Aretaeus noted 
that as affected individuals wasted away, they passed increasing amounts of 
urine as if there was “liquefaction of flesh and bones into urine”. The 
complete term “diabetes mellitus” was coined in 1674 by Thomas Willis, 
personal physician to King Charles II. Mellitus is Latin for honey, which is 
how Willis described the urine of diabetics (“as if imbued with honey and 
sugar”).[38] 
Up until the mid-1800s, the treatments offered for diabetes varied 
tremendously. Various “fad” diets were prescribed, and the use of opium 
was suggested, as were bleeding and other therapies. The most successful 
treatments were starvation diets in which calorie intake was severely 
restricted. Naturally, this was intolerable for the patient and at best extended 
life expectancy for a few years.[38] 
A breakthrough in the puzzle of diabetes came in 1889. German 
physicians Joseph von Mering and Oskar Minkowski surgically removed the 
pancreas from dogs. The dogs immediately developed diabetes. Now that a 
link was established between the pancreas gland and diabetes, research 
focused on isolating the pancreatic extract that could treat diabetes. When 
Dr. Frederick Banting took up the challenge of isolating a pancreatic extract, 
he was met with much skepticism. Many great physiologists had tried and 
failed to isolate an internal secretion from the pancreas. But Banting, a 
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surgeon, persisted and in May 1921, he began work in the laboratory of 
Professor John Macloed in Toronto, Canada. Charles Best, a medical student 
at the time, worked as his assistant.[37] 
To concentrate what is known as insulin, Banting tied the pancreatic 
ducts of dogs. The pancreatic cells that released digestive enzymes (and 
could also destroy insulin) degenerated, but the cells that secreted insulin 
were spared. Over several weeks the pancreas degenerated into a residue 
from which insulin could be extracted. In July 1921, a dog that had had its 
pancreas surgically removed was injected with an extract collected from a 
duct-tied dog. In the two hours that followed the injection, the blood sugar 
level of the dog fell, and its condition improved. Another de-pancreatized 
(diabetic-like) dog was kept alive for eight days by regular injections until 
supplies of the extract, at that time called "isletin", were exhausted. Further 
experiments on dogs showed that extracts from the pancreas caused a drop 
in blood sugar, caused glucose in the urine to disappear, and produced a 
marked improvement in clinical condition. So long as the extract was being 
given, the dogs were kept alive. The supply of the extract was improved: the 
pancreas of different animals were used until that of the cow was settled 
upon. This extract kept a de-pancreatized dog alive for 70 days. Dr. J. 
Collip, a biochemist, was drafted to continue improving the purity of the 
pancreas extract, and later, Best carried on this work. A young boy, Leonard 
Thompson, was the first patient to receive insulin treatment. On January 11, 
1922, aged 14 and weighing only 64 pounds, he was extremely ill. The first 
injections of insulin only produced a slight lowering of blood sugar level. 
[38] 
The extract still was not pure enough, and abscesses developed at the 
injection site. Collip continued to refine the extract. Several weeks later, 
Leonard was treated again and showed a remarkable recovery. His blood 
sugar levels fell, he gained weight and lived for another 13 years. He died 
from pneumonia at the age of 27.[38] 
During the spring of 1922, Best increased the production of insulin to 
enable the treatment of diabetic patients coming to the Toronto clinic. Over 
the next 60 years, insulin was further refined and purified, and long-acting 
and intermediate types were developed to provide more flexibility. A 
revolution came with the production of recombinant human DNA insulin in 
1978. Instead of collecting insulin from animals, new human insulin could 
be synthesized.[38] 
The impact of diabetes and of diabetes –related illnesses place an 
enormous burden on the health care systems of most of countries throughout 
the world. It has been estimated that by the year 2025, 300 million people 
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will have diabetes- a remarkable 5.4% of the world‟s projected population. 
[30] 
Diabetes is an example of a disease with an unmet global medical 
need and conforms to the “commonality of interest” principle of the Priority 
Medicines Project. The increases in diabetes projected over the next several 
decades require a global strategy for prevention, treatment and medicine 
development. [30] 
There are many oral agents that improve glucose control in diabetes 
by either improving insulin secretion or improving insulin action if diet and 
exercise are not working. The pharmaceutical industry considers 
development of effective diabetes medications as a major goal. For patients 
requiring insulin, current methods of insulin administration cannot reproduce 
the body‟s ability to precisely control blood glucose and other metabolic 
variables. [30] 
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AIM OF STUDY 
 
 
 The first goal is to describe diabetes mellitus as the disease, focusing 
mostly in the following information: 
 Definition 
 Classification 
 Clinical manifestations 
 Complications 
 Diagnosis 
 Non-pharmacological and pharmacological treatment 
 
 
The second goal is divided in 3 parts: 
 Firstly to give evidence-based guidelines and recommendations for 
the management, non-pharmacological and pharmacological treatment 
of type 1 and type 2 diabetes mellitus in children and adults, including 
the newer oral hypolipidemics. 
 Secondly to give more impact to type 2 than type 1 diabetes mellitus, 
and to show the dangerous level that it has reached nowadays for 
children and adults. 
 Thirdly to describe the general situation of diabetes mellitus in 
Cyprus, in European Union, and the global situation, giving more 
impact to European Union. After to make comparison between Cyprus 
and the European Union, and between Cyprus and the global situation. 
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METHODOLOGY 
 
 
The methods used in this diploma thesis are mainly literature searches 
in electronic form found in websites and different databases, or in the form 
of books, journals and published articles. 
 
 The approach used in the first section of the theoretical part is: 
 
 General description of diabetes mellitus using books and literature 
from several websites, including the World Health Organization 
(WHO) and the National Institute for Health and Clinical Excellence 
(NICE). 
 Supplementary therapy using various journals from the Cyprus 
Diabetic Association (CDA), and websites about Diabetes Diet and 
Nutrition. 
 
The approach used in the second section of the results is: 
 
 NICE guidelines and recommendations for management and 
pharmacotherapy of type 1 and type 2 diabetes in children and adults, 
including the newer agents in the market, using the official website of 
NICE. 
 Published articles using mostly PubMed and Medline databases 
(English language), concerning the epidemiology of diabetes in 
Cypriot population, using keywords as: Diabetes mellitus in Cyprus, 
Cypriot diabetics, Type 1 diabetes in Cyprus, Type 2 diabetes in 
Cyprus. General description of diabetes mellitus in Cyprus was found 
using various journals from the Cyprus Diabetic Association (CDA), 
and some websites concerning diabetes mellitus in EU were also 
considered. 
 Situation about diabetes in Europe and the EU was found using 
literature in electronic form from several websites concerning the 
European Diabetes Foundation and the European Diabetes 
Epidemiology Study group. 
 Global situation about diabetes mellitus was found searching 
databases in electronic form, mostly PubMed (English language), 
using keywords as: Global prevalence of diabetes, Diabetes in the 
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world, Global diabetes problem. Also search was made in the official 
website of the International Diabetes  Foundation. 
 Tables and figures were found after searching in the official website 
of the World Health Organization (WHO), and the National Centre for 
Health Statistics (NCHS). 
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I. THEORETICAL PART 
 
 
1.1  Definition 
 
 
 
Diabetes mellitus is a syndrome characterized by hyperglycemia 
resulting from absolute or relative impairment in insulin secretion and/or 
insulin action. [30] 
Patients with type I diabetes mellitus, also known as insulin-
dependent diabetes mellitus or juvenile-onset diabetes, may develop diabetic 
ketoacidosis. Patients with type II diabetes mellitus, also known as non-
insulin-dependent diabetes mellitus, may develop non-ketotic 
hyperglycaemic-hyperosmolar coma. Common late microvascular 
complications include retinopathy, nephropathy and peripheral and 
autonomic neuropathies. Macrovascular complications include 
atherosclerotic coronary and peripheral arterial disease. [37] 
 
 
1.2  Classification and Pathogenesis 
 
 
1.2.1  Type I diabetes mellitus 
 
Although it may occur at any age, type I diabetes mellitus most 
commonly develops in childhood or adolescence and is the predominant 
type of diabetes mellitus diagnosed before age 30. This type of diabetes 
accounts for 10 to 15% of all cases of diabetes mellitus and is characterized 
clinically by hyperglycemia and a propensity to diabetic ketoacidosis. The 
pancreas produces little or no insulin. [37] 
About 80% of patients with type I diabetes mellitus have specific 
HLA phenotypes associated with detectable serum islet cell cytoplasmic 
antibodies and islet cell surface antibodies (antibodies to glutamic acid 
decarboxylase and to insulin are found in a similar proportion of cases). [33] 
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In these patients, type I diabetes mellitus results from a genetically 
susceptible, immune-mediated, selective destruction of > 90% of their 
insulin-secreting β cells. Their pancreatic islets exhibit insulitis, which is 
characterized by an infiltration of T lymphocytes accompanied by 
macrophages and B lymphocytes and by the loss of most of the β cells, 
without involvement of the glucagons-secreting α cells. Cell-mediated 
immune mechanisms are believed to play the major in the β-cell destruction. 
The antibodies present at diagnosis usually become undetectable after a few 
years. They may be primarily a response to β-cell destruction, but some are 
cytotoxic for β cells and may contribute to their loss. The clinical onset of 
type I diabetes mellitus may occur in some patients years after the insidious 
onset of the underlying autoimmune process. Screening for these antibodies 
is included in numerous ongoing preventive studies. [30] 
 In white populations, a strong association exists between type I 
diabetes mellitus diagnosed before age 30 and specific HLA-D phenotypes 
( HLA-DR3, HLA-DR4, and HLA-DR3/HLA-DR4). One or more genes that 
convey susceptibility to type I diabetes mellitus are believed to be located 
near or in the HLA-D locus on chromosome 6. Specific HLA-DQ alleles 
appear to be more intimately related to risks for or protection from type I 
diabetes mellitus than HLA-D antigens, and evidence suggests that genetic 
susceptibility to type I diabetes mellitus is probably polygenic. Only 10 to 
12% of newly diagnosed children with type I diabetes mellitus have a first-
degree relative with type I diabetes mellitus, and the concordance rate for 
type I diabetes mellitus in monozygotic twins is < or equal 50%. Thus, in 
addition to the genetic background, environmental factors affect the 
appearance of type I diabetes mellitus. Such environmental factors may be 
viruses(congenital rubella, mumps, and coxsackie B viruses may incite the 
development of autoimmune β-cell destruction) and exposure to cow‟s milk 
rather than maternal milk in infancy( a specific sequence of albumin from 
cow‟s milk may cross-react with islet protein). [37] 
 
 
1.2.2  Type II diabetes mellitus 
 
Type II diabetes mellitus is usually the type of diabetes diagnosed in 
patients > 30 years old, but it also occurs in children and adolescents. It is 
characterized clinically by hyperglycemia and insulin resistance. Diabetic 
ketoacidosis is rare. Although most patients are treated with diet, exercise, 
and oral drugs, some patients intermittently or persistently require insulin to 
control symptomatic hyperglycemia and prevent non-ketotic 
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hyperglycaemic-hyperosmolar coma. The concordance rate for type II 
diabetes mellitus in monozygotic twins is > 90%. Type II 
diabetes mellitus is commonly associated with obesity, especially of the 
upper body (visceral/abdominal), and often presents after a period of weight 
gain. Impaired glucose tolerance associated with aging is closely correlated 
with the typical weight gain. Type II diabetes mellitus patients with 
visceral/abdominal obesity may have normal glucose levels after losing 
weight. [8] 
 Type II diabetes mellitus is a heterogeneous group of disorders in 
which hyperglycemia results from both an impaired insulin secretory 
response to glucose and decreased insulin effectiveness in stimulating 
glucose uptake by skeletal muscle and in restraining hepatic glucose 
production( insulin resistance). However, insulin resistance is common, and 
most patients with insulin resistance will not develop diabetes, because the 
body compensates by adequately increasing insulin secretion. Insulin 
resistance in the common variety of type II diabetes mellitus is not the result 
of genetic alterations in the insulin receptor or the glucose 
transporter.However,genetically determined postreceptor intracellular 
defects likely play a role. The resulting hyperinsulinemia may lead to other 
common conditions, such as obesity(abdominal),hypertension, 
hyperlipidemia and coronary artery disease(the syndrome of insulin 
resistance). [37] 
 Genetic factors appear to be the major determinants for the 
development of type II diabetes mellitus, yet no association between type II 
diabetes mellitus and specific HLA phenotypes or islet cell cytoplasmic 
antibodies has been demonstrated.( An exception is a subset of non-obese 
adults with detectable islet cell cytoplasmic antibodies who carry one of the 
HLA phenotypes and who may eventually develop type I diabetes mellitus. 
The pancreatic islets in type II diabetes mellitus retain β-cells in ratios to α-
cells that are not consistently altered, and normal β-cell mass appears to be 
preserved in most patients. Pancreatic islet amyloid, resulting from a 
deposition of amylin, is found in a high percentage of type II diabetes 
mellitus patients at autopsy, but its relationship to the pathogenesis of type II 
diabetes mellitus is not well established. [29] 
 Before diabetes develops, patients generally lose the early insulin 
secretory response to glucose and may secrete relatively large amounts of 
proinsulin. In established diabetes, although fasting plasma insulin levels 
may be normal or even increased in type II diabetes mellitus patients, 
glucose-stimulated insulin secretion is clearly decreased. The decreased 
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insulin levels reduce insulin-mediated glucose uptake and fail to restrain 
hepatic glucose production. [37] 
 Hyperglycemia may not only be a consequence but also a cause of 
further impairment in glucose tolerance in the diabetic patient (glucose 
toxicity) because hyperglycemia decreases insulin sensitivity and increases 
hepatic glucose production. Once a patient‟s metabolic control improves, the 
insulin or hypoglycaemic drug dose is usually lowered. [3] 
 Some cases of type II diabetes mellitus occur in young, nonobese 
adolescents (maturity-onset diabetes of the young) with an autosomal 
dominant inheritance. Many families with maturity-onset diabetes of the 
young have a mutation in the glucokinase gene. Impairments in insulin 
secretion and in hepatic glucose regulation have been demonstrated in these 
patients. [37] 
 
 
 
1.2.3  Children with type 2 diabetes mellitus 
 
Can children get Type 2 diabetes? 
Type 2 diabetes used to be practically unheard of in people under 30. 
That explains the other common name for the disease: adult-onset diabetes. 
Not long ago, almost all children with diabetes suffered from the Type 1 
form of the disease, which means their bodies couldn't produce enough 
insulin. And Type 2 diabetes, in which the pancreas may produce normal 
insulin levels but cells become resistant to it, typically took decades to 
develop. [4] 
But Type 2 diabetes isn't just for adults anymore. The number of 
children and adolescents with the condition (most of whom are diagnosed in 
their early teens) has skyrocketed within the last 20 years, prompting the 
journal Diabetes Care to call it an "emerging epidemic." While Type 1 
diabetes is still more prevalent among children nationwide, experts estimate 
that Type 2 diabetes has grown from less than 5 percent in 1994 to 30 to 50 
percent of all newly diagnosed cases of the disease in more recent years. [2] 
 Because young children who are obese are more likely to become 
diabetic when they're older, experts are paying particular attention to how 
 15 
much -- or how little -- preadolescents eat and exercise. Disease researchers 
at the Centers for Disease Control and Prevention (CDC) recently made the 
stunning prediction that one in three children born in the United States in 
2000 will likely develop Type 2 diabetes unless they get more exercise and 
improve their diets. The prediction was especially serious for Latino 
children. Without changes in diet and exercise, their odds of developing 
diabetes as they grow older was about 50-50. [23] 
Type 2 is not usually as life-threatening or dramatic as Type 1 at the 
time of diagnosis, but it does increase the likelihood that children may 
develop serious long-term complications such as blindness, kidney disease, 
and heart disease. If untreated, the child may also eventually develop 
circulatory problems severe enough to require amputation of limbs. [35] 
With proper medical treatment and a self-care program that 
incorporates exercise, glucose monitoring, and nutrition, however, your 
child can likely keep his or her blood sugar under control and avoid serious 
complications. [1] 
 
Which children are at risk for Type 2 diabetes? 
As many as 92 percent of all children and adolescents with Type 2 
diabetes are significantly overweight, and about 40 percent are clinically 
obese. Indeed, researchers suspect that increases in obesity among young 
people is driving the new epidemic. [4] 
There has long been a statistical link between obesity and Type 2 
diabetes, but exactly why millions of overweight people develop Type 2 
diabetes has long been a medical mystery. In January 2001, a study 
published in Nature suggested why millions of overweight people go on to 
develop the disease. The missing link, researchers argued, was a hormone 
they called resistin, which is produced by fat cells and incites tissues to resist 
insulin, the hormone our bodies need to turn blood sugar into energy. 
However in 2003, scientists scuttled this theory in a human study published 
in the Journal of Clinical Endocrinology and Metabolism. These scientists 
found no correlation between resistin levels and body mass index, lipid 
profile, or insulin resistance levels. [5] 
Other studies have suggested that the type of obesity -- or where you 
store your fat -- may make a difference as well. Those who store it around 
the middle (the so-called apple shape) are at higher risk of developing 
diabetes. Some experts believe that high-carbohydrate, low-fiber diets are 
part of the problem. Finally, because exercise makes your body's muscle 
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cells more sensitive to insulin, a sedentary lifestyle is a risk factor. If your 
child rarely plays outside or exercises, then, he or she may be at greater risk 
of the disease. [6] 
For unknown reasons, Native Americans, African-Americans, Asian-
Americans, Pacific Islanders, and Latinos are also especially vulnerable to 
the disease. (One theory is that people whose hunter or gatherer ancestors 
led "feast or famine" lives developed a "thrifty gene," which allowed for 
very efficient fat storage.) Researchers at Children's Hospital in Cincinnati 
found that, compared with children of European descent, African-American 
boys and girls were 3.5 and 6.1 times more likely to develop Type 2 
diabetes, respectively. Doctors at a Southern California diabetes clinic 
recently reported that 31 percent of young Mexican-American patients had 
the Type 2 variety, compared with 3 percent of the white children. [7] 
Other factors can also put children at risk. If close family members 
have the disease or if a mother develops diabetes during pregnancy, for 
example, children are significantly more likely to develop the disease. [2] 
 
 
What are the warning signs of Type 2 diabetes? 
Many children go for years before they have symptoms that they 
recognize as a problem, but most children with Type 2 diabetes are 
diagnosed before they ever show symptoms. Still, it pays to be cautious, 
especially if your child is at high risk for the disease. Watch for these signs: 
increased urination, extreme thirst, increased appetite, and weight loss. One 
other potential sign of Type 2 diabetes is a skin condition called acanthosis 
nigricans. As many as 70 percent of children with Type 2 diabetes have this 
condition, which is characterized by a patch of extremely dark, velvety, and 
rippled skin, most often on an underarm or the back of the neck. [28] 
Specific blood and urine tests are used to diagnose Type 2 diabetes, 
and these are not usually part of a routine physical exam. You should ask the 
doctor about these tests, especially if there's a history of the disease in the 
family and if your child is overweight. And again, Native Americans, 
Latinos, African-Americans, Asian-Americans, and Pacific Islanders are at 
increased risk. [3] 
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Are there everyday consequences for children with Type 2 diabetes? 
Yes. Although Type 2 is usually not as serious in the shortrun as Type 
1 -- and is generally easier to control -- there are several possible day-to-day 
effects of the disease. The American Diabetes Association (ADA) lists these 
common ones:  
• Headache 
• Blurred vision 
• Thirst 
• Frequent urination 
• Dry, itchy skin 
 
Long-term consequences are also a serious concern. If not controlled 
at an early age, Type 2 diabetes can lead to complications such as blindness, 
renal failure, hypertension, heart disease, and the need for amputations by 
the time children reach their 20s. [3] 
 
How is childhood Type 2 diabetes treated? 
Unlike children with Type 1 diabetes, those with Type 2 usually don't 
need insulin shots to control their blood sugar levels. In fact, most can 
manage their disease simply by eating fewer calories, cutting back on fats 
and sugars, and getting more exercise. Remember, kids get most of their 
lifestyle cues (not to mention their groceries) from their parents. By serving 
healthy foods, encouraging physical activity, and educating the family about 
diabetes, parents can make a huge contribution to their children's health. [22] 
When lifestyle changes aren't enough -- or when they can't be made -- 
your child may need insulin shots. Some Sulfonylurea drugs and metformin 
can also help bring a child's blood sugar under control. [8] 
And soon child may not have to stick themselves with insulin. In 
January 2006, the FDA approved inhaled insulin as a treatment option for 
Type 1 and Type 2 diabetes in adults. This new type of insulin, which goes 
by the name Exubera, comes in powder form and is the first new insulin 
delivery option since the discovery of the hormone in the 1920s. [10] 
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For Type 2 diabetics, inhaled insulin may be used alone, along with 
pills that control blood sugar, or with longer acting insulin. However the 
drug is not for smokers -- something to think about should it become 
available to children even if your child just lives with one -- and it is not 
recommended for people with asthma or bronchitis. [9] 
While research on the effectiveness and safety of these drugs on 
children looks promising, they do have some side effects. [9] 
 
 
Can childhood Type 2 diabetes be prevented? 
The key to preventing Type 2 diabetes in children -- and adults for 
that matter -- is avoiding obesity. Give your child a balanced diet (including 
lots of fiber, whole-grain foods, and fruits and vegetables), avoid sugary 
junk foods and sodas, and encourage your child to get lots of exercise. By 
encouraging children to exercise and eat right from an early age, parents 
may be able to put a stop to this epidemic and set their children on the road 
to a long, healthy life. [1] 
 
 
1.3  Symptoms and Signs 
 
 After many researches from physicians to diabetic patients, they have 
concluded that diabetes mellitus has diverse initial presentations. Type I 
diabetes mellitus usually presents with symptomatic hyperglycemia or 
diabetic ketoacidosis. Type II diabetes mellitus may present with 
symptomatic hyperglycemia or non-ketotic hyperglycaemic-hyperosmolar 
coma, but is frequently diagnosed in asymptomatic patients during a routine 
medical examination or when patients present with clinical manifestations of 
a late complication. [36] 
 Often following the acute onset of type I diabetes mellitus, there is 
substantial secretion of insulin. Type I diabetes mellitus patients may 
experience a honeymoon period characterized by a long phase of  near-
normal glucose levels without any treatment. [34] 
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 Symptomatic hyperglycemia: Polyuria followed by polydipsia and 
weight loss occur when elevated plasma glucose levels cause marked 
glucosuria and an osmotic diuresis,resulting in dehydration. Hyperglycemia 
may also cause blurred vision, fatigue, and nausea and lead to various fungal 
and bacterial infections. In type II diabetes mellitus, symptomatic 
hyperglycemia may persist for days or weeks before medical attention is 
sought; in women, type II diabetes mellitus with symptomatic 
hyperglycemia is frequently associated with itching due to vaginal 
candidiasis. [18] 
 
 
 
1.4  Complications 
 
 
 Late complications: Late complications occur after several years of 
poorly controlled hyperglycemia. Glucose levels are increased in all cells 
except where there is insulin-mediated glucose uptake (mainly muscle), 
resulting in an increase in glycolysation and in the activity of other 
metabolic pathways, which may be caused by complications. Most 
microvascular complications can be delayed, prevented, or even reversed by 
tight glycemic control, ie , achieving near-normal fasting and postprandial 
glucose levels, reflected by near-normal glycosylated haemoglobin (Hb 
A1c). Macrovascular disease such as atherosclerosis may lead to 
symptomatic coronary artery disease, claudication, skin breakdown, and 
infections. Although hyperglycemia may accelerate atherosclerosis, many 
years of hyperinsulinemia preceding the onset of diabetes (with insulin 
resistance) may play a major initiating role. Amputation of a lower limp for 
severe peripheral vascular disease, intermittent claudication, and gangrene 
remains common. Background retinopathy (the initial retinal changes seen 
on ophthalmoscopic examination or in retinal photographs) does not 
significantly alter vision, but it can progress to macular edema or 
proliferative retinopathy with retinal detachment or hemorrhage, which can 
cause blindness. About 85% of all diabetics eventually develop some degree 
of retinopathy. [17] 
 Diabetic nephropathy develops in about one third of type I diabetes 
mellitus patients and in a smaller percentage of type II diabetes mellitus 
patients. In type I diabetes mellitus patients, GFR may be increased initially 
with hyperglycemia. After about 5 years of type I diabetes mellitus, 
clinically detectable albuminuria (> or equal mg/L), which is unexplained by 
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other urinary tract disease, may develop. Albuminuria signals a progressive 
decrease in GFR with a high likelihood of development of end-stage renal 
disease within 3 to 20 years (median, 10 years). Albuminuria is almost 2.5 
times higher in type I diabetes mellitus patients with diastolic BP>90mm Hg 
than in those with diastolic BP<70mm Hg. Thus, both hyperglycemia and 
hypertension accelerate the progression to end-stage renal disease. Diabetic 
nephropathy is usually asymptomatic until end-stage renal disease develops, 
but it can cause the nephrotic syndrome. Albuminuria and renal disease may 
be prevented or delayed with the ACE inhibitor captopril. While aggressive 
treatment of hypertension prevents the deterioration of renal function, ACE 
inhibitors have shown added benefits over other classes of antihypertensives. 
In fact, ACE inhibitors prevent proteinurea in hypertensive and 
nonhypertensive diabetics. Recent evidence suggests that ACE inhibitors 
also help prevent retinopathy. [35] 
 Diabetic neuropathy commonly occurs as a distal, symmetric, 
predominantly sensory polyneuropathy that causes sensory deficits, which 
begin with and are usually most marked by a stocking-glove distribution. 
Diabetic polyneuropathy may cause cause numbness, tingling, and 
paresthesias in the extremities and, less often, debilitating, severe, deep-
seated pain and hyperesthesias. Ankle jerks are usually decreased or absent. 
Other causes of polyneuropathy must be excluded. Acute, painful 
mononeuropathies affecting the 3
rd
, 4
th
, or 6
th
 cranial nerve as well as other 
nerves, such as  the femoral, may spontaneously improve over weeks to 
months, occur more frequently in older diabetics, and are attributed to nerve 
infarctions. Autonomic neuropathy occurs primarily in diabetics with 
polyneuropathy and can cause postural hypotension, disordered sweating, 
impotence and retrograde ejaculation in men, impaired bladder function, 
delayed gastric emptying (sometimes with dumping syndrome), esophageal 
dysfunction, constipation or diarrhea, and nocturnal diarrhea. A decrease in 
heart rate response to the Valsalva maneuver or on standing and unchanged 
heart rate variation during deep breathing are evidence of autonomic 
neuropathy in diabetics. [3] 
 Foot ulcers and joint problems are important causes of morbidity in 
diabetes mellitus. The major predisposing cause is diabetic polyneuropathy-
the sensory denervation impairs the perception of trauma from such common 
causes  as ill-fitting shoes or pebbles. Alterations in proprioception lead to 
an abnormal pattern of weight bearing and sometimes to the development of 
Charcot‟s joints. [30] 
 The risk of infection from fungi and bacteria is increased because of 
decreased cellular immunity caused by acute hyperglycemia and circulatory 
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deficits caused by chronic hyperglycemia. Peripheral skin infections and oral 
and vaginal thrush are most common. A mycotic infection may be the initial 
process, leading to wet interdigital lesions, cracks, fissures, and ulcerations 
that favour secondary bacterial invasion. Patients with infected foot ulcers 
frequently feel no pain because of neuropathy and have no systemic 
symptoms until late in a neglected course. Deep ulcers and particularly 
ulcers associated with any detectable cellulitis require immediate 
hospitilization, since systemic toxicity and permanent disability may 
develop. Osteomyelitis should be ruled out by bone scan. Early surgical 
debridement is an essential part of management, but amputation is 
sometimes necessary. [35] 
 
 
 
 
 
1.5  Diagnosis  
 
 
 In asymptomatic patients, diabetes mellitus is established when the 
diagnostic criterion for fasting hyperglycemia recommended by the National 
Diabetes Data Group is met: a plasma (or serum) glucose level of > or equal 
with 140 mg/dL (> or equal with 7.77 mmol/L) after an overnight fast on 
two occasions in an adult or child. Recently, the American Diabetes 
Association recommended that fasting plasma glucose levels of > 126 
mg/dL (>6.99 mmol/L) be considered diagnostic for diabetes mellitus. [3] 
 An oral glucose tolerance test may be helpful in diagnostic type II 
diabetes mellitus in patients whose fasting glucose is between 115 and 140 
mg/dL ( 6.38 and 7.77 mmol/L) and in those with a clinical condition that 
might be related to undiagnosed diabetes mellitus( eg polyneuropathy, 
retinopathy). However, various conditions other than diabetes mellitus, such 
as effects of drugs, and normal aging can cause abnormalities in the oral 
glucose tolerance test. [3] 
 The National Diabetes Data Group also recommends criteria for the 
diagnosis of impaired glucose tolerance  in patients who do not meet the 
oral glucose tolerance test diagnostic criteria for diabetes mellitus. Patients 
with impaired glucose tolerance may be at increased risk of developing 
fasting or symptomatic hyperglycemia, but in many patients the condition 
does not progress or it resolves. [33] 
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1.6  Diabetic diseases 
 
 
1.6.1  Insulinopathies 
 
Rare cases of diabetes mellitus, with the clinical characteristics of type 
II diabetes mellitus, result from the heterozygous inheritance of a defective 
gene, leading to secretion of insulin that does not bind normally to the 
insulin receptor. These patients have greatly elevated plasma 
immunoreactive insulin levels associated with normal plasma glucose 
responses to exogenous insulin. [26] 
 
1.6.2  Diabetes attributed to pancreatic disease 
 
Chronic pancreatitis, particularly in alcoholics, is frequently 
associated with diabetes. Such patients lose both insulin-secreting and 
glucagon-secreting islets. Therefore, they may be mildly hyperglycaemic 
and sensitive to low doses of insulin. Given the lack of effective 
counterregulation( exogenous insulin that is unopposed by glucagon), they 
frequently suffer from rapid onset of hypoglycaemia. In Cyprus,diabetes 
mellitus is commonly observed in young, severely malnourished patients 
with severe protein deficiency and pancreatic disease; these patients are not 
diabetic-ketoacidosis-prone but may require insulin. [27] 
 
1.6.3  Diabetes associated with other endocrine diseases 
 
Type II diabetes mellitus can be secondary to Cushing‟s syndrome, 
acromegaly, pheochromocytoma, glucagonoma, primary aldosteronism, or 
somatostatinoma. [14] 
Most of these disorders are associated with peripheral or hepatic insulin 
resistance. Many patients will become diabetic once insulin secretion is also 
decreased. The prevalence of type I diabetes mellitus is increased in patients 
with certain autoimmune endocrine diseases, eg, Graves‟ disease 
Hashimoto‟s thyroiditis, and idiopathic Addison‟s disease. [28] 
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1.6.4  Insulin-resistant diabetes associated with acanthosis nigricans 
(type A and type B insulin resistance syndromes) 
 
Two rare syndromes result from marked insulin resistance at the 
insulin receptor level associated with acanthosis nigricans. Acanthosis 
nigricans is a velvety hyperpigmentation on the neck, axillae, and groin and 
is probably the skin manifestation of severe and chronic hyperinsulinemia. 
Type A results from genetic alterations in the insulin receptor. Type B 
results from circulating antibodies to the insulin receptor and may be 
associated with other evidence of autoimmune disease. These cases are very 
rare in Cyprus. [24] 
 
1.6.5  Lipoatrophic diabetes 
 
This is a rare syndrome among Cypriot people in which insulin-
resistant diabetes mellitus is associated with an extensive symmetric or 
virtually complete disappearance of subcutaneous adipose tissue. It has been 
linked to genetic alterations in the insulin receptor. [30] 
 
1.6.6  Diabetes induced by β-cell toxins 
 
Vacor, a rodenticide, is cytotoxic for human islets and can cause type 
I diabetes mellitus. Streptozocin can induce experimental diabetes in rats but 
rarely causes diabetes in humans. [37] 
 
 
 
 
1.7  Non-pharmacological treatment 
 
 
1.7.1  Diet management 
 
 
Type 1 and type 2 diabetic patients should be carefull with their diet 
and the proportions of carbohydrates, fat and proteins that they consume and 
furthermore they should be carefull with the timing, size and the 
composition of meals to control their glucose levels. 
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In insulin-treated diabetics, diet management aims to restrict 
variations in the timing, size, or composition of meals, which could make the 
prescribed insulin regimen inappropriate and result in hypoglycaemia or 
marked postprandial hyperglycemia. All insulin-treated patients require 
detailed diet management, including a prescription for their total daily 
caloric intake; guidelines for proportions of carbohydrate, fat, and protein in 
their diets; and instruction on distributing calories among individual meals 
and snacks. A professional dietitian can tailor the diet plan and education to 
meet the patient‟s individual needs. Flexibility, however, helps maintain 
patient motivation. Publications are available from the American Diabetes 
Association and other sources for diet planning and patient education. 
Exchange list providing information on the carbohydrate, protein, fat, and 
caloric contents of individual servings are used to translate the dietary 
prescription into a diet plan, which should contain foods that the patient likes 
to eat, provided there is no specific reason to exclude a particular food. 
Foods with similar exchange values ( ie, similar calories and contents of 
carbohydrate, protein, and fat) may have different effects on postprandial 
hyperglycemia in any individual diabetic. However, exchange lists are 
helpful in reducing the variation in the size and composition of the patient‟s 
usual breakfasts, lunches, dinners and snacks. [6] 
 
In obese type II diabetes mellitus patients, the aims of diet 
management are losing weight and controlling hyperglycemia. The diet 
should meet the patient‟s minimum daily protein requirement (0.9 g/kg) and 
be designed to induce a gradual and sustained weight loss ( about 2 lb/week) 
until ideal body weight is approached and maintained. A dietitian can assist 
in developing a diet that the patient will follow. Increased physical activity 
in sedentary obese type II diabetes mellitus patients is valuable and may 
decrease insulin resistance over time. Diabetics with hypertension should be 
treated with ACE inhibitors, which have been shown to be more protective 
against coronary artery disease than Ca channel blockers. [6] 
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1.7.2  Supplementary therapy to diabetes mellitus 
 
 
1.7.2.1  Nutritional Therapy  
Meal Planning  
A non-diabetic produces the constantly varying amounts of insulin 
necessary for obtaining energy from glucose. A diabetic cannot achieve this 
balance. Beyond the basic requirements to provide adequate calories and 
necessary nutrients, there are marked differences in diet strategy for the two 
major groups of diabetic patients: Type 1 insulin-dependent non-obese 
patients and Type 2 obese patients who do not require insulin. Patients who 
are on insulin therapy must schedule their meals to provide regular caloric 
intake. In overweight patients, special attention must be given to total caloric 
consumption. [31] 
There is no need to disproportionately restrict the intake of 
carbohydrates in the diet of most diabetic patients. In fact, Dr. H.P. 
Himsworth demonstrated in 1930 that if carbohydrates were taken out of the 
diet and replaced by either protein or fats, a person would quickly develop 
insulin resistance and diabetes. The key here is in the choice of high-fibre 
complex carbohydrates. [31] 
One of the first dietary rules for all diabetics is to avoid all sugar and 
foods containing sugar, such as pastry, candy and soft drinks. While these 
refined sugars and other simple carbohydrates like white flour must be 
carefully watched, most diabetics are actually encouraged to eat more 
complex carbohydrates - the same bulky, fibre-rich unprocessed foods that 
are now recommended for everyone. Vegetables are ideal. For example, a 
diabetic can eat a large plate of spinach that contains as much carbohydrate 
as a tablespoonful of sugar, without suffering any ill effects. [7] 
Spinach, asparagus, broccoli, cabbage, string beans and celery are 
among the so-called "Food Exchange Group A" vegetables that the 
American Diabetes Association (ADA) says can be generously included in 
the diabetic diet. What makes these complex carbohydrates special is their 
ability to slow down the body's absorption of carbohydrates by helping to 
delay the emptying of the stomach and thereby smoothing out the absorption 
of sugars into the blood. Whole grain cereals also have this ability. [7] 
Fully one third of diabetic patients in clinical surveys have hyper-
lipidemia, clearly indicating the need for dietary management. The most 
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sensible approach is to limit the amount of fat in their diet and to substitute 
polyunsaturated fats for the saturated type when possible. Fish and poultry 
are especially recommended instead of fatty cuts of meat. Greasy, fried 
foods are strongly discouraged. [6] 
Obesity is much more likely in people who eat a high-fat diet, which 
is often a high calorie diet, since each gram of fat contains nine calories 
instead of the four calories in each gram of protein or carbohydrate. With 
obesity comes an increased risk of a variety of problems, not the least of 
which is adult-onset diabetes. [6] 
Overweight diabetics, by carefully calculating the proper daily calorie 
intake for their body weight and activity level, and never exceeding it, can 
usually bring their weight down to an optimal level - a level which is 
actually 10% less than the standard height and weight charts recommend. 
[31]  
The need to reduce fat is reflected in the standard diet and food 
exchange lists prepared by the ADA that restricts the intake of fat to 35% of 
calories. The reduction of saturated fats to one-third of the fat intake by 
substituting poultry, veal and fish for red meats, and the reduction of 
cholesterol to less than 300 mg/day are stressed. The carbohydrate content is 
40-50 per cent of total calories, with unrefined carbohydrates recommended 
to the exclusion of refined and simple carbohydrates. [6] 
Currently another diet, known as the 'HCF (high-carbohydrate high 
plant-fibre) diet' popularised by James Anderson has substantial support and 
validation in the scientific literature as the diet of choice in the treatment of 
diabetes. It is high in cereal grains, legumes and root vegetables and restricts 
simple sugar and fats. The calorie intake consists of 70-75 per cent complex 
carbohydrates, 15-20 per cent protein and only 5-10 per cent fat, and the 
total fibre content is almost 100 grams/day. The positive metabolic effects of 
the HCF diet are many: reduced after-mealtime hyperglycaemia and delayed 
hypoglycaemia; increased tissue sensitivity to insulin; reduced cholesterol 
and triglyceride levels with increased HDL-cholesterol levels; and 
progressive weight reduction. [7] 
In general the HCF diet is adequate for the treatment of diabetes. 
However improvements can be made, primarily by substituting more natural 
(primitive) foods wherever possible. The Modified HCF or MHCF diet 
recommends a higher intake of legumes, along with restrictions of several 
foods allowed on the HCF diet, namely processed grains, and excludes fruit 
juices, low fibre fruits, skimmed milk and margarine. It is noteworthy that if 
patients resume a conventional ADA diet, their insulin requirements return 
to prior levels. [6] 
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Many diabetics have found it beneficial to eat smaller, more frequent 
meals, rather than the two or three big meals most people consume daily. 
Researchers have found that multiple frequent feedings tend to keep blood 
cholesterol levels lower, for the diabetic and non-diabetic alike. [4] 
 
 
1.7.2.2  Vitamins and Minerals  
 
Generally a well-balanced diet rich in vitamins and minerals is one of 
the most important factors in the control of diabetes and prevention of 
diabetic complications. One reason for stressing the need for proper levels of 
nutrients is the excessive urination experienced by the diabetic. [31] 
Normally the body reabsorbs glucose and other water-soluble 
nutrients. When glucose rises to levels above 160-170mg/dl, as it does quite 
frequently in even well controlled diabetic patients, it acts as an osmotic 
diuretic. This process overwhelms the kidney's ability to reabsorb glucose 
and other water-soluble nutrients, thus the increased urination, and 
substantial losses of nutrients such as vitamins B-1, B-6 and B-12 and the 
minerals magnesium, zinc and chromium pass out along with the urine. 
Consequently diabetes and its complications are as much a result of 
nutritional wasting as of elevated blood sugar. [22] 
In an article in the American Journal of Clinical Nutrition where 247 
studies were reviewed, it was found that Type 1 (IDDM) diabetics generally 
had deficiencies in zinc, calcium, magnesium and the more active form of 
vitamin D. Those with Type 2 diabetes (NIDDM) generally were found to be 
low in zinc and magnesium and often low in vitamins B6 and C. [6] 
The physical body needs all these water-soluble nutrients to maintain 
the integrity of its organ system. Perhaps one of the most important nutrients 
is magnesium. The medical literature is full of studies showing that diabetic 
patients invariably have lower blood levels of magnesium than normal, also 
with higher urinary losses. In a landmark study conducted in 1978 by Dr. P. 
McNair and titled Hypomagnesemia, a Risk Factor in Diabetic Retinopathy, 
it was demonstrated that diabetics with the lowest magnesium levels had the 
most severe retinopathy, and that low magnesium levels were linked 
significantly to retinopathy more than any other factor. The article argued 
that simply elevating the magnesium concentration with supplements would 
protect the eyes. [36] 
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Other nutrients are also attracting serious attention. Researchers in 
London recently reported that vitamin D is essential for the islet cells in the 
pancreas to be able to secrete insulin properly10. Their studies have shown 
that individuals with the lowest vitamin D levels experienced the worst 
blood sugar-handling problems and had a greater risk of developing 
diabetes. They found that those with greatest risk of developing vitamin D 
deficiency included the elderly who were either institutionalised or stayed 
indoors, those living in climates where sunlight is scarce several months a 
year, and those with indoor sedentary jobs. In an effort to eliminate the 
widespread vitamin D deficiencies in the institutionalised elderly, over 80% 
of those individuals are now being given 800 IU/day vitamin D3 
supplements. [36] 
Other researchers have found that the diabetic is unable to convert 
carotene into vitamin A. It is advisable therefore for the diabetic to ingest at 
least the recommended dietary allowance of vitamin A from a non-carotene 
source such as fish-liver oil. Diabetics and others on low-fat diets often need 
supplemental amounts of this fat-soluble nutrient. Also recommended is a 
vitamin E supplement, ranging from 400-1200 IU per day and a vitamin C 
supplement ranging from 1000-4000 mg per day to help prevent small-
vessel disease of the extremities. [26] 
Brewer's yeast is another food supplement that is recommended for 
the diabetic patient. The yeast is a rich source of chromium-containing GTF 
(glucose tolerance factor) which is able to potentiate the insulin in our 
bodies. GTF also contains amino acids such as glutamic acid, glycine, and 
cysteine. Both brewer's yeast (9 gm/day) and trivalent chromium (150-1000 
mcg/day) have been shown to significantly improve blood sugar metabolism 
when taken for several weeks to months. As a side benefit it has also been 
found that brewer's yeast and chromium supplementation lower elevated 
total cholesterol and total lipids, and significantly raise the levels of HDL-
cholesterol, the beneficial or protective fraction of cholesterol. [31] 
Chromium is found in foods as both inorganic and organic salts. 
Brewer's yeast contains a form of chromium with high bioavailability, 
chromiumÇdinicotinic acidÇglutathione complex. The bioavailability of 
chromium in liver, American cheese and wheat germ is also relatively high. 
Chromium is also available from a variety of sources including whole 
grains, potatoes and apples with skins, spinach, oysters, carrots, and chicken 
breast. Recent research has identified certain varieties of barley grown in 
Mesopotamia to be some of the richest sources of chromium. [31] 
A 1996 study of 180 Type 2 diabetics, carried out in China under the 
guidance of Dr. Richard A. Anderson11, found that 500 mcg of chromium 
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picolinate taken twice daily for four months lowered the fasting glucose 
level to an average of 129, compared to 160 in those taking a placebo. In 
addition, glycosylated haemoglobin (a test of longer-term glucose tolerance) 
averaged an almost normal level of 7.5% in those taking chromium - 
significantly lower than those on placebo. All of the effects of chromium 
appear to be due to increased insulin sensitivity. [19] 
Another exceptionally useful trace mineral to combat diabetes is 
vanadium, which lowers blood sugar by mimicking insulin and improving 
the cells' sensitivity to insulin. A growing body of human research shows 
that vanadium compounds, most notably vanadyl sulfate, consistently 
improve fasting glucose and other measures of diabetes. These benefits were 
often extended for weeks after the mineral supplementation was 
discontinued. [31] 
In addition to taking supplements, diabetics are encouraged to eat the 
widest possible variety of permitted foods to ensure getting the full range of 
trace elements and other nutrients. It is interesting to note that certain 
nutrients like vitamins B1, B2, B12, pantothenic acid, vitamin C, protein and 
potassium - along with small frequent meals containing some carbohydrate - 
can actually stimulate production of insulin within the body. [27] 
 
Cautions  
1. Fish oil capsules or supplements containing large amounts of para-
aminobenzoic acid (PABA) can elevate blood sugar.  
2. Supplements containing cysteine interfere with absorption of insulin by 
cells.  
3. Extremely large dosages of vitamins B1 or C may inactivate insulin. 
Dosages listed above are within normal ranges. [6] 
 
 
1.7.2.3  Botanical medicines  
 
Since antiquity, diabetes has been treated with plant medicines. The 
following herbs appear to be the most effective, are relatively non-toxic and 
have substantial scientific documentation to attest to their efficacy. [31] 
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European Blueberry (Vaccinium myrtillus)  
Traditional herbalism places great value on European Blueberry 
leaves, a.k.a. Bilberry, as a natural method of controlling or lowering blood 
sugar levels when they are slightly elevated. Results have shown the leaves 
have an active ingredient with a remarkable ability to reduce excess sugar in 
the blood. To use, steep two to three handfuls of leaves in 4 cups hot water 
for half an hour. Drink three cups a day. Modern research has demonstrated 
the berries or extract of the berries offer even greater benefit. The standard 
dose of the extract is 80-160 mg three times per day. [31] 
 
Gymnema sylvestre  
Native to the tropical forests of India. Used to lower blood sugar and 
help repair damage to pancreatic cells. Therapeutic dosage is 400 mg/day. A 
good source is a preparation by Natrol as a single herb 5:1 extract containing 
300 mg. [6] 
Bitter melon (Momordica Charantia)  
Composed of several compounds with confirmed anti-diabetic 
properties. 50-60 ml (about 2 oz) of fresh juice per day has shown good 
results in clinical trials. Charantin, the key ingredient extracted by alcohol, is 
a hypoglycaemic agent composed of mixed steroids more potent than the 
drug Tolbutamide that is often used to treat diabetes. [6] 
Onion and Garlic  
The common bulbs, onion and garlic, have significant blood sugar-
lowering action as well as lowering lipids, inhibiting platelet aggregation, 
and reducing blood pressure. [7] 
Fenugreek  
Fenugreek seeds have demonstrated anti-diabetic effects in 
experimental and clinical studies. Administration of the defatted seed (in 
daily doses of 1.5-2g/kg) reduces fasting and after-meal glucose, glucagon, 
somatostatin, insulin, total cholesterol and triglycerides, while increasing 
HDL-cholesterol levels. [31] 
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Salt Bush (Atriplex halimu)  
Rich in fibre, protein, and numerous trace minerals, including 
chromium. Human studies in Israel have demonstrated improved blood 
glucose regulation and glucose tolerance in Type 2 diabetes. Dosage used in 
this study was 3g per day. [8] 
Ginkgo biloba  
Gingko biloba extract improves blood flow in the peripheral tissues of 
the arms, legs, fingers and toes and is therefore an important medicine in the 
treatment of peripheral vascular disease. It has also been shown to prevent 
diabetic retinopathy. Dosage of the extract standardised to contain 24% 
ginkgo flavoglycosides is 40-80 mg three times per day. [31] 
Ginseng (Panax ginseng)  
Ginseng, besides reducing fasting blood sugar levels and body weight, 
can elevate mood and improve psycho-physiological performance. 
Therapeutic dosage is 100-200 mg daily. [7] 
Traditional Chinese medicine 
 
According to Traditional Chinese Medicine, diabetes mellitus is a 
disorder characterized by Yin deficiency with dryness, heat and dampness. 
Yin deficiency is the underlying cause of the disease; dryness and heat 
represent the symptoms and signs; and dampness is reflected in increased 
blood glucose. Diabetes mellitus is most closely related to Wasting (Xiao 
Ke) syndrome, which can be categorized into Upper, Middle and Lower 
Wasting (Xiao Ke) syndrome, with the organs affected including the Lungs, 
Stomach and Kidneys, respectively. [31] 
Upper Wasting (Xiao Ke) Syndrome is characterized by Lung heat 
drying up body fluids. Symptoms are fidgeting, polydipsia, dry red tongue 
(with or without cracks), with a thin, yellow coat, and a forceful, rapid pulse 
(especially at the cun position). Middle Wasting (Xiao Ke) Syndrome is 
characterized by Stomach fire damaging fluids, with such symptoms as 
polyphagia, constant hunger with good appetite, red tongue with a yellow 
coat, and a slippery, forceful, rapid pulse. Lower Wasting (Xiao Ke) 
Syndrome is sub-divided into Kidney Yin deficiency or Kidney Yin and 
Yang deficiencies. Kidney Yin deficiency is characterized by symptoms 
such as polyuria (especially at night), red tongue with little or no coat, and a 
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deep, thready, rapid pulse; Kidney Yin and Yang deficiency is characterized 
by polyuria (especially at night), teethmarks on both sides of the tongue, 
pale red tongue with a white coat, and a deep, thready, weak pulse. [31] 
Despite the similarities between Diabetes and Wasting (Xiao Ke) 
Syndrome, it is important to keep in mind that they are not identical. Both 
Diabetes and Wasting (Xiao Ke) syndrome may be characterized by the 
presence of the three P's: polyuria, polydypsia and polyphagia. Diabetes, 
however, is defined as an increase in blood glucose levels, with or without 
the presence of the three P's. In addition, Diabetes may have many 
complications not present in Wasting (Xiao-Ke) syndrome, such as visual 
disturbances, impotence, amenorrhea, and frequent infections. Conversely, 
the presence of the three P's constitutes diagnosis of Wasting (Xiao-Ke) 
Syndrome. Polyuria, polydypsia and polyphagia may be caused by factors 
other than diabetes, such as fever, dehydration, or kidney disease. 
Understanding the similarities and differences between the two is essential 
for an accurate diagnosis and for optimal treatment of the patient. [31] 
 
 
1.7.2.4  Chinese herbal treatments 
 
Chinese herbs are very effective in treating patients with Type II, 
NIDDM. When prescribed correctly, Chinese herbs lower blood glucose 
levels, manage common signs and symptoms, and treat the complications of 
diabetes mellitus. Patients generally respond to herbal treatment within 
three-to-four weeks, with significant reduction in blood glucose levels and 
little fluctuation throughout the day. However, some patients may require up 
to six-to-eight weeks. For patients with Type I, IDDM, Chinese herbs are 
used in conjunction with insulin to manage symptoms and complications. 
Chinese herbs can also reduce the frequency and dosage of insulin 
injections. However, it is important to keep in mind that herbs cannot 
replace insulin, and patients with IDDM will still require insulin injections. 
[18] 
Equilibrium 
Equilibrium is the formula of choice for treating diabetes mellitus. 
From the perspective of Western medicine, Equilibrium contains herbs with 
excellent hypoglycemic effects, lowering blood glucose levels and reducing 
synthesis of fatty tissues. In addition, Equilibrium contains herbs that lower 
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blood cholesterol levels and improve blood circulation to the coronary 
arteries and peripheral parts of the body--thus managing common 
complications of diabetes, such as hyperlipidemia, atherosclerosis, coronary 
artery disease, peripheral neuropathy, etc. [31] 
In terms of Chinese therapeutic actions, Equilibrium nourishes Lung, 
Stomach and Kidney Yin, clears heat, and dries dampness. It can be used for 
patients with Upper, Middle or Lower Wasting (Xiao Ke) syndromes. It 
effectively manages the three cardinal symptoms of Wasting (Xiao Ke) 
syndrome: polydipsia, polyphagia and polyuria. [28] 
Equilibrium treats both the cause and the complications of diabetes 
mellitus. American ginseng (xi yang shen) greatly replenishes the vital 
essence of the body and promotes the secretion of body fluids, to treat 
polydipsia. Gypsum (shi gao) and anemarrhena (zhi mu) are a pair 
commonly used to treat heat in the Middle Burner (Jiao). They sedate 
Stomach fire and suppress appetite to relieve polyphagia. Scrophularia (xuan 
shen) enters the Lungs, Stomach and Kidneys to simultaneously replenish 
vital essence and clear heat. According to Oriental Medicine, an elevated 
glucose level is equivalent to excess retention of dampness in the body. 
Therefore, astragalus (huang qi) and dioscorea (shan yao) are used to tonify 
Qi and strengthen the Spleen to enhance its functions to dispel dampness. 
With their aromatic properties, white atractylodes (bai zhu) and atractylodes 
(cang zhu) strengthen the Spleen and directly dry dampness. Salvia root (dan 
shen) and carthamus (hong hua) invigorate blood circulation and enhance 
the overall effectiveness of the herbs by improving micro-circulation. 
Activation of blood circulation also reduces the risk of atherosclerosis by 
preventing buildup of cholesterol on the inner walls of blood vessels. Lastly, 
lotus embryo (lian zi xin) and lotus stamen (lian xu) tonify the Kidney and 
control frequent urination. [28] 
 
Modification of Herbal Treatment Based on Wasting (Xiao-Ke) 
Syndrome 
Equilibrium is the essential herbal formula used to lower blood 
glucose if the patient shows no other significant complications. If diabetic 
patients exhibit prominent signs and symptoms of Upper, Middle or Lower 
Wasting (Xiao Ke) syndromes, treatment must be modified by combining 
Equilibrium with the following formulas: 
1. Upper Wasting (Xiao-Ke) Syndrome is characterized by Lung heat 
drying body fluids, resulting in symptoms such as fidgeting, polydipsia, a 
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dry red tongue (with or without cracks) with a thin, yellow coat, and a 
forceful, rapid, pulse (especially at the cun position). Patients with Upper 
Wasting (Xiao-Ke) Syndrome should combine Equilibrium with Ginseng & 
Gypsum Combination (Bai Hu Jia Ren Shen Tang). 2. Middle Wasting 
(Xiao-Ke) Syndrome is characterized by Stomach fire damaging the fluids, 
leading to such symptoms as polyphagia, constant hunger with good 
appetite, a red tongue with a yellow coat, and a slippery, forceful, rapid 
pulse. Patients with Middle Wasting (Xiao-Ke) Syndrome should combine 
Equilibrium with Rehmannia & Gypsum Combination (Yu Nu Jian). 3. 
Lower Wasting (Xiao Ke) Syndrome with Kidney Yin deficiency is 
characterized by such symptoms as polyuria (especially at night), a red 
tongue with little or no coat, and a deep, thready, rapid pulse. Patients with 
Lower Wasting (Xiao Ke) syndrome with Kidney Yin deficiency should 
combine Equilibrium with Rehmannia Six Formula (Liu Wei Di Huang 
Wan). 4. Lower Wasting (Xiao Ke) Syndrome with Kidney Yin and Yang 
deficiencies is characterized by polyuria (especially at night), teethmarks on 
both sides of the tongue, a pale red tongue with a white coat, and a deep, 
thready, weak pulse. Patients with Lower Wasting (Xiao Ke) Syndrome with 
Kidney Yin and Yang deficiencies should combine Equilibrium with 
Rehmannia Eight Formula (Ba Wei Di Huang Wan). [31] 
 
Modification of Herbal Treatment Based on Complications 
If diabetic patients exhibit prominent signs and symptoms of 
complications, treatment must be modified by combining Equilibrium with 
the following formulas: 
1. For patients with high cholesterol, combine with Cholisma. 2. For 
patients with hypertension, combine with Gentiana Complex or Gastrodia 
Complex. 3. For patients with chronic buildup of cholesterol leading to 
coronary artery disease, combine with Circulation. 4. For patients with 
blurred vision or vision impairment, combine with Nourish. 5. For patients 
with impotence due to diabetic complications, combine with Vitality For 
Men. 6. For patients with recurrent urinary tract infections, combine with 
Gentiana Complex. [31] 
 
Cautions 
 
Patients should not stop using drug treatments abruptly as there is a 
risk of hyperglycemia or diabetic ketoacidosis. Herbal and drug treatments 
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should overlap for 1 to 2 weeks before patients are to begin tapering off drug 
treatments to ensure adequate control of blood glucose levels. [19] 
Concurrent use of drugs and herbal treatment may have synergistic 
effects on lowering the blood glucose levels. During the transition period 
when the patients take both drugs and herbs, their blood glucose levels 
should be monitored at least twice daily to assess the effectiveness of the 
treatment and to avoid hypoglycemia. Dosage must be adjusted as needed to 
keep blood glucose within the normal range. Herbal treatment may reduce 
the dosage and frequency of insulin injections needed; however, it can never 
replace insulin, especially in insulin dependent diabetes mellitus (IDDM) 
patients. Patients with IDDM should always be treated with insulin, or a 
combination of insulin and herbs. [6] 
 
 
1.7.3  Lifestyle instructions 
 
 
Lifestyle adjustments are absolutely critical for short-term 
management and long-term recovery of diabetes. Patients should be 
encouraged to engage in regular daily exercise, sleep by 10 p.m. to enhance 
restoration of Yin elements in the body, and eliminate sugar, carbohydrates 
and caffeine from the diet. Additional dietary advice may be useful based on 
the primary organ systems affected. [30] 
 
For patients with Type II, NIDDM, Equilibrium in combination with 
diet and exercise provides excellent clinical results. Most patients will get 
satisfactory clinical results within three-to-four weeks of beginning herbal 
treatment. Maximum effectiveness may require up to six-to-eight weeks of 
herbal treatment. Clinical effects include a significant reduction in blood 
glucose levels and less fluctuation throughout the day. [31] 
Diabetes mellitus is defined simply as a rise in blood glucose levels. 
The clinical manifestations of the disease, however, are much more 
complicated than its definition. Patients with chronic diabetes mellitus are 
frequently plagued by various complications, such as visual disturbances, 
prolonged healing of wounds, frequent recurrences of infections, impotence, 
etc., which must be addressed within the overall treatment strategy. [35] 
Diagnosis and treatment of the most common and complex 
endocrinologic disorder continues to pose a challenge for health care 
practitioners. Diabetes mellitus commonly may go undiagnosed as patients 
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with early stages of Type II, NIDDM are often asymptomatic. Also, as 
patients with chronic Type II, NIDDM often have a wide variety of 
complications, diabetes mellitus is frequently overlooked or mis-diagnosed. 
Once the correct diagnosis is made, diabetes and its complications can be 
effectively managed by both western drugs and herbal remedies. In 
conclusion, herbal medicine offers a safe and effective alternative for 
patients with diabetes mellitus. [7] 
 
General considerations: The Diabetes Control and Complications 
Trial proved that hyperglycemia is responsible for most of the long-term 
microvascular complications of diabetes. It is demonstrated a linear 
relationship between the levels of Hb A1c and the rate at which 
complications developed. Other studies have suggested that Hb A1c <8% is 
a threshold below which most complications can be prevented. Thus, 
therapy for type I diabetes mellitus should try to intensify metabolic control 
to lower Hb A1c while avoiding hypoglycaemic episodes. However, 
treatment must be individualized and should be modified when 
circumstances make any risk of hypoglycaemia  unacceptable (eg, in patients 
with a short life expectancy and in those with cerebrovascular or cardiac 
disease) or when the patient‟s risk of hypoglycaemia is increased (eg, in 
patients who are unreliable or who have autonomic neuropathy). [30] 
  
Diet to achieve weight reduction is most important in overweight 
patients with type II diabetes mellitus. If improvement in hyperglycemia is 
not achieved by diet, trial with an oral drug should be started. [6] 
  
Patient education, together with diet and exercise, is essential to 
ensure the effectiveness of the prescribed therapy, to recognise indications 
for seeking immediate medical attention, and to ensure appropriate foot care. 
On each physician visit, the patient should be assessed for symptoms or 
signs of complications, including a check of feet and pulses and sensation in 
the feet and legs, and a urine test for albumin. Periodic laboratory evaluation 
includes lipid profile, BUN and serum creatinine levels, ECG, and an annual 
complete ophthalmologic evaluation. [31] 
 Because diabetics are at increased risk of acute renal failure, x-ray 
studies that require IV injection of contrast dyes should be performed only 
when absolutely necessary and only when the patient is well hydrated. [30] 
 Hypercholesterolemia or hypertension increases the risks for specific 
late complications and requires special attention and appropriate treatment. 
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Although β-blockers(eg, propranolol) can be used safely in most diabetics, 
they can mask the β-adrenergic symptoms of insulin-induced hypoglycaemia 
and can impair the normal counterregulatory response. Thus, ACE inhibitors 
and calcium antagonists are often the drugs of choice. [35] 
 
 Plasma glucose monitoring: All patients should learn self-
monitoring of glucose, and insulin-treated patients should be taught to adjust 
their insulin doses accordingly. Glucose levels can be tested with easy-to-use 
home analysers using a drop of fingertip blood. A spring-powered lancet is 
recommended to obtain the fingertip blood sample. The frequency of testing 
is determined individually. Insulin-treated diabetic patients ideally should 
test their plasma glucose daily before meals, 1 or 2 hours after meals, and at 
bedtime. However, in practice, two to four measurements may be obtained 
each day at different times, so that an overall assessment can be made after a 
week or so of treatment. [33] 
 Most physicians periodically determine glycosylated haemoglobin 
(Hb A1c) to estimate plasma glucose control during the preceding 1 to 3 mo. 
Hb A1c is the stable product of nonenzymatic glycosylation of the θ-chain 
of Hb by plasma glucose and is formed at rates that increase with increasing 
plasma glucose levels. In most laboratories, the normal Hb A1c level is 
about 6%; in poorly controlled diabetics, the level ranges from 9 to 12%. Hb 
A1c is not a specific test for diagnosing diabetes; however, elevated Hb A1c 
often indicates existing diabetes. [37] 
 Another test is of the fructosamine level. Fructosamine is formed by 
a chemical reaction of glucose with plasma protein and reflects glucose 
control in the previous 1 to 3 weeks. Therefore, this assay may show a 
change in control before Hb A1c and is often helpful when intensive 
treatment is applied and in short-term clinical trials. [37] 
 Patients with type I diabetes mellitus should be instructed to test for 
urine ketones with commercially available reagent strips and be advised to 
test for urine ketones whenever they develop symptoms of a cold, flu, or 
other intercurrent illness; nausea, vomiting, or abdominal pain; or polyuria; 
or if they find an unexpectedly high plasma glucose level on self-
monitoring. Testing for ketones in all urine samples is recommended for 
type I diabetes mellitus patients who exhibit persistent, rapid, and marked 
fluctuations in their degree of hyperglycemia. [3] 
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1.8  Pharmacotherapy 
 
 
The strategy of pharmacotherapy of diabetes mellitus is to control the 
disease either is type 1 or type 2. The current pharmacotherapy concering 
type 1 is with the use of insulin and mainly the insulin analogues. 
Pharmacotherapy concerning type 2 diabetes mellitus is with the use of oral 
hypoglycemic agents from which the most important are the sulphonylureas, 
metformin, thiazolidinediones and acarbose. 
 
1.8.1  Insulin therapy 
 
 
Human insulin is often preferred in initiating insulin treatment 
because it is less antigenic than animal-derived varieties. However, 
detectable insulin antibody levels, usually very low, develop in most insulin-
treated patients, including those receiving human insulin preparations. [34] 
 Insulin is routinely provided in preparations containing 100 U/Ml (U-
100 insulin) and is injected subcutaneously with disposal insulin syringes. 
The 1/2 –mL syringes are generally preferred by patients who routinely 
inject doses of < or equal with 50 U, because they can be read more easily 
and facilitate the accurate measurement of smaller doses. A multiple-dose 
insulin injection device( NovolinPen), commonly referred to as an insulin 
pen, is designed to use a cartridge containing several day‟s dosage. Insulin 
should be refrigerated but never frozen; however, most insulin preparations 
are stable at room temperature for months, which facilitates their use at work 
and when travelling. [35] 
 Insulin preparations are classified as short-acting( rapid-
acting),intermediate-acting, or long-acting. The critical determinant of the 
onset and duration of action of an insulin preparation is the rate of insulin 
absorption from the injection site. [36] 
 Rapid-acting insulins include regular insulin, which is a preparation of 
zinc insulin crystals in a suspending solution; regular insulin is the only 
insulin preparation that can be given intravenously. Lispro, a form of regular 
insulin that is genetically engineered with a substitute of one amino acid, 
provides more rapid absorption of insulin and therefore may be administered 
with food. Semilente insulin is a slightly slower rapid-acting insulin, 
containing zinc insulin microcrystals in an acetate buffer. Intermediate-
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acting insulin includes neutral protamine Hagedorn, which contains a 
stoichiometric mixture of regular and protamine zinc insulin, and Lente, 
which contains 30% Semilente insulin and 70% Ultralente insulin in an 
acetate buffer. Long-acting protamine zinc insulin contains insulin that is 
negatively charged, combined with an excess of positively charged fish 
sperm protamine. Ultralente contains large zinc insulin crystals in an acetate 
buffer. [35] 
  
 
 
 
1.8.1.1  Insulin preparations 
 
 
Mixtures of insulin preparations with different onsets and durations 
of action are frequently given in a single injection by drawing measured 
doses of two preparations into the same syringe immediately before use. The 
manufacturers recommend that Semilente be mixed only with Lente or 
Ultralente to maintain the same buffer solution. However, individual doses 
of regular insulin and neutral protamine Hagedorn or Lente insulin are 
commonly drawn up into the same syringe to combine rapid- and 
intermediate-acting insulin in a single injection. A preparation that contains 
a mixture of 70% neutral protamine Hagedorn and 30% regular human 
semisynthetic insulin( Novolin 70/30 or Humulin 70/30) is also available, 
but its fixed ratio of intermediate- to rapid-acting insulin may restrict its use. 
Protamine zinc insulin must always be injected separately, because it 
contains an excess of protamine. [34] 
 
  
1.8.1.2  Insulin therapy in adults and children 
 
 
Initiation of insulin therapy in adults: In Diabetes Control and 
Complications Trial, type I diabetes mellitus patients received an average 
total dose of about 40 U insulin a day. Because type II diabetes mellitus 
patients are insulin resistant, they require more insulin. Thus, those who are 
severely hyperglycaemic and obese may be started on about 40 U insulin a 
day. The initial total daily dose may be divided so that ½ will be 
administered before breakfast, ¼ before dinner, and ¼ at bedtime. Because 
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of severe insulin resistance, type II diabetes mellitus patients may need twice 
that much and often more. After the initial dose is selected, adjustments in 
the amounts, types, and timing are made based on plasma glucose 
determinations. The dose is adjusted to maintain preprandial plasma glucose 
between 80 and 150 mg/dL( 4.44 and 8.33 mmol/L). Increments in insulin 
dose are generally restricted to 10% at a time, and the effects are assessed 
over about 3 days before any further increment is made. More rapid 
adjustments of regular insulin are indicated if hypoglycaemia threatens. [30] 
 
 Initiation of insulin therapy in children: Children who present at an 
early stage of type I diabetes mellitus with moderately hyperglycemia but 
without ketonuria or acidosis may be started with a single daily 
subcutaneous injection of 0.3 to 0.5 U/kg of intermediate-acting insulin 
alone. Children who present with both hyperglycemia and ketonuria but who 
are not acidotic or dehydrated may be started on 0.5 to 0.7 U/kg of 
intermediate-acting insulin and then supplemented by subcutaneous 
injections of 0.1 U/kg of regular insulin at 4- to 6- hours intervals. Insulin 
doses are usually adjusted to maintain preprandial plasma glucose levels 
between 80 and 150 mg/DL( 4.44 and 8.33 mmol/L) or sometimes between 
80 and 120 mg/DL(4.44 and 6.66 mmol/L). [28] 
 
1.8.1.3  Insulin schedules 
 
The goal of insulin therapy is to control hyperglycaemic surges after 
meals and to provide baseline levels that support normal glucose 
metabolism. Regimens must always be individualized, and some diabetics 
will achieve tight control with highly idiosyncratic schedules. However, the 
approach should include: 
1. Bedtime intermediate-acting insulin. This helps control 
nocturnal hepatic glucose production. Starting the day with lower 
morning glucose levels will improve glucose tolerance throughout 
the day. Bedtime insulin is associated with less weight gain than is 
daytime insulin alone. Bedtime insulin is also a reasonable way to 
initiate insulin therapy in type II diabetes mellitus patients who are 
not controlled by oral drugs alone. [8] 
2. Before-breakfast mixed insulin. This often is accomplished with 
a mixture of about 30% short-acting and 70% intermediate-acting 
insulin. Most diabetic patients will need about half the daily insulin 
dose before breakfast. [8] 
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3. Before-lunch-and-dinner regular insulin. For tight control, 
supplemental rapid-acting insulin should be taken before meals. 
The dose should be taken 15 to 30 min before a meal for regular or 
Semilente and with a meal for Lispro. [8] 
 
1.8.1.4  Insulin administration 
 
Multiple subcutaneous insulin injections: These are designed to 
maintain normal or near-normal plasma glucose levels throughout the day in 
patients with type I diabetes mellitus. Such treatment may increase the risks 
for frequent and severe episodes of hypoglycaemia. Patients should be 
highly motivated, well educated in diabetes mellitus, informed of the risks 
and uncertain benefits, competent in self-monitoring of glucose, and under 
the supervision of a physician experienced in its use. In a typical multiple 
subcutaneous insulin injection regimen, about 25% of the total daily dose is 
given as intermediate-acting insulin at bedtime, with additional doses of 
rapid-acting insulin given before each meal( a four-dose regimen). Type I 
diabetes mellitus patients may require intermediate- or long-acting insulin in 
the morning to give coverage throughout the day. The patient adjusts daily 
dosage on the basis of self-monitoring of glucose before each meal and at 
bedtime; the plasma glucose level between 2 and 4 AM is assessed at least 
once/week. [22] 
 
Continuous subcutaneous insulin infusion: This mode of intensive 
insulin treatment in patients with type I diabetes mellitus involves a small 
battery-powered infusion pump that provides a continuous subcutaneous 
infusion of rapid-acting insulin through a small needle, usually inserted in 
the abdominal wall. The pump is programmed to infuse a selected basal rate 
of insulin, supplemented by manually triggered or programmed increased 
rates before each meal. The patient measures glucose levels several times a 
day to adjust the dosage. Control obtainable with this method is superior to 
that obtained with multiple injections. Hypoglycemic episodes are common 
with pump therapy, especially during the establishment of metabolic control. 
However, once metabolic control is established, pumps are not associated 
with more hypoglycaemia than are multiple injections. Experimental pump 
implants and intraperitoneal deliveries of insulin to the portal system may 
prove superior. However, the indwelling needle increases the risk of 
infections at needle sites. [22] 
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Insulin treatment of brittle diabetes: Brittle diabetics are type I 
diabetes mellitus patients who exhibit frequent, rapid swings in glucose 
levels without apparent cause. [22] 
Brittle diabetes is most common in patients with no residual insulin 
secretory capacity. The metabolic processes through which insulin affects 
the plasma levels of glucose, albumin-bound free fatty acids, and ketones are 
normally regulated by shifts in the balance between the effects of insulin and 
the opposing effects of glucagon ( in the liver) and the adrenergic autonomic 
nervous system. These counterregulatory mechanisms are independently 
regulated and normally increased during fasting, exercise, and other 
conditions that require protection against hypoglycaemia. Insulin doses must 
be adequate to deal with a sudden increase in counterregulatory mechanisms 
and to prevent rapidly developing symptomatic hyperglycemia and 
hyperketonemia, but this frequently produces transient plasma insulin 
excess. [30] 
Many of these patients improve when switched to a modified multiple 
subcutaneous insulin regimen that provides most of the daily insulin as a 
rapid-acting insulin in daily adjusted dosages before each meal, with some 
intermediate-acting insulin in the morning, before the evening meal, or at 
bedtime. The aim is not to maintain the diurnal plasma glucose level in near-
normal range but to stabilize the fluctuations in a range that prevents 
symptomatic hyper- and hypoglycaemia. [22] 
 
 
1.8.1.5  Complications of insulin treatment 
 
Hypoglycemia may occur because of an error in insulin dosage, a 
small or missed meal, or unplanned exercise ( patients are usually instructed 
to reduce their insulin dose or to increase their carbohydrate intake before 
planned exercise) or without apparent cause. Patients are taught to recognize 
symptoms of hypoglycaemia, which usually respond rapidly to the ingestion 
of sugar. All diabetics should carry candy, lumps or sugar, or glucose 
tablets. An identification card, bracelet, or necklace indicating that the 
patient is an insulin-treated diabetic aids in recognizing hypoglycaemia in 
emergencies. Close family members should be instructed to administer 
glucagon with an easy-to-use injection device. Emergency medical 
personnel, after confirming the hypoglycaemia with a glucostick, should 
initiate therapy with a rapid bolus injection of 25 mL of 50% glucose 
solution followed by a continuous IV infusion of glucose. [8] 
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The dawn phenomenon refers to the normal tendency of the plasma 
glucose to rise in the early morning hours before breakfast, which is 
frequently exaggerated in patients with type I diabetes mellitus and in some 
patients with type II diabetes mellitus. Fasting glucose levels rise because of 
an increase in hepatic glucose production, which may be secondary to the 
midnight surge of growth hormone. In some patients with type I diabetes 
mellitus, nocturnal hypoglycaemia may be followed by a marked increase in 
fasting plasma glucose with an increase in plasma ketones (Somogyi 
phenomenon). Thus, both the dawn and Somogyi phenomena are 
characterized by morning hyperglycemia, but the latter is due to rebound 
(counterregulation) hyperglycemia. The frequency with which the latter 
phenomenon actually occurs is disputed. When it is suspected, the patient 
should wake between 2 and 4 AM to monitor blood glucose levels. If 
intermediate insulin is administered at bedtime, the dawn and Somogyi 
phenomena can often be prevented. [34] 
Local allergic reactions at the site of insulin injections are less 
common with purified porcine and human insulins. These reactions can 
produse immediate pain and burning, followed after several hours by local 
erythema, pruritus, and induration, the latter sometimes persisting for days. 
Most reactions spontaneously disappear after weeks of continued insulin 
injection and require no specific treatment, although antihistamines are 
sometimes used. [35] 
Generalized insulin allergy (usually to the insulin molecule) is rare 
but can occur when treatment is discontinued and restarted after a lapse of 
months or years. Such reactions may occur with any type of insulin, 
including human biosynthetic insulin. Symptoms usually develop shortly 
after an injection and may include urticaria, angioedema, pruritus, 
bronchospasm, and, in some cases, circulatory collapse. Treatment with 
antihistamines may suffice, but epinephrine and IV glucocorticoids may be 
required. If continued insulin treatment is required after the condition 
stabilizes, skin testing with a panel of purified insulin preparations and 
desensitization should be performed by an experienced physician. [34] 
Insulin resistance is an increase in insulin requirement to > or equal 
with 200 U/day and is associated with marked increases in the plasma 
insulin-binding capacity. Most patients treated with insulin for > or equal 
with 6 mo develop antibodies to insulin. The relative antigenicity of purified 
insulin preparations is bovine >porcine>human, but genetic factors also 
affect individual response. Circulating insulin-binding antibodies can modify 
the pharmacokinetics of free insulin, but treatment usually is not adversely 
affected. In patients with insulin resistance, switching to purified porcine or 
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human insulin may lower the requirement. Remission may be spontaneous 
or may be induced in some type II diabetes mellitus patients who can stop 
insulin treatment for 1 to 3 mo. Prednisone may decrease insulin 
requirements within 2 weeks; treatment is usually initiated with about 30 mg 
bid and is tapered as the requirements decrease. [34] 
Local fat atrophy or hypertrophy at injection sites is relatively rare 
and usually improves by switching to human insulin and injecting it directly 
into the affected area. No specific treatment of local fat hypertrophy is 
required, but injection sites should be rotated. [35] 
 
 
 
1.8.2  Oral antidiabetic drugs 
 
 
These drugs are used for type II diabetes mellitus but not for type I 
diabetes mellitus because they cannot prevent symptomatic hypeglycemia or 
diabetic ketoacidosis in such patients. Oral hypoglycaemic drugs are the 
biguanides, the α-glucosidase inhibitors, and the insulin sensitizers 
(thiazolidinediones[glitazones]). [8] 
 
1.8.2.1  Sulfonylureas 
 
The sulfonylureas lower plasma glucose primarily by stimulating 
insulin secretion. Secondary effects on improving peripheral and hepatic 
insulin sensitivity may be due to the decrease in both glucose toxicity and 
insulin clearance. Sulfonylureas differ in potency and duration of action. All 
of the sulfonylureas are metabolized in the liver, but only tolbutamide and 
tolazamide are inactivated exclusively by the liver. About 30% of 
chlorpropamide is normally excreted in the urine, and the principal hepatic 
metabolite of acetohexamide is highly active and excreted in urine; both 
drugs carry an increased risk of prolonged hypoglycaemia in patients with 
impaired renal function and in the elderly. The 2
nd
-generation sulfonylureas 
(such as glipizide and glyburide) are about 100 times more potent than the 
1
st
-generation ones, are absorbed rapidly, and are metabolized mainly in the 
liver. Clinically, the 2
nd
-generation sulfonylureas are similar in effectiveness. 
[35] 
Allergic reactions and other side effects ( eg, cholestatic jaundice) 
are relatively uncommon. Acetohexamide may be used in patients who are 
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allergic to other sulfonylureas. Chlorpropamide and acetohexamide should 
not be used in patients with impaired renal function. In addition, 
chlorpropamide should not be used in elderly patients, because it can 
potentiate the action of antidiuretic hormone, often leading to hyponatremia 
and a deterioration in mental status, which in an elderly patient may often 
not be recognized as a drug-induced effect. [35] 
For the initial treatment, many authorities prefer the shorter-acting 
sulfonylureas, and most do not recommend using a combination of different 
sulfonylureas. Treatment is started with a low dose, which is adjusted after 
several days until a satisfactory response is obtained or the maximum 
recommended dosage is reached. About 10 to 20% of patients fail to respond 
to a trial of treatment (primary failures), and patients who fail to respond to 
one sulfonylurea often fail to respond to others. Of patients who initially 
respond, 5 to 10% per year experience secondary failures. In such cases, 
insulin may be added to sulfonylurea treatment. [8] 
Hypoglycemia is the most important complication of sulfonylurea 
treatment. Hypoglycemia can occur in patients treated any of the 
sulfonylureas but occurs most frequently with long-acting ones (glyburide, 
chlorpropamide). Sulfonylurea-induced hypoglycaemia can be severe and 
may last or recur for days after treatment is stopped, even when it occurs in 
patients treated with tolbutamide, whose usual duration of action is 6 to 12 
hours. A mortality rate of 4.3% in patients hospitalized with sulfonylurea-
induced hypoglycaemia has been reported recently. Therefore, all 
sulfonylurea-treated patients who develop hypoglycaemia should be 
hospitalized, because even if they respond rapidly to initial treatment for 
hypoglycaemia, they must be closely monitored for 2 to 3 days. Most of 
these patients may not require further treatment with sulfonylureas. [35] 
 
 
1.8.2.2  Biguanides (Metformin) 
 
Metformin has been used as primary therapy in type II diabetes 
mellitus patients for over 30 years in Cyprus. It has been recently approved 
for use in the USA. It acts by decreasing hepatic glucose production and 
may improve insulin sensitivity in those who lose weight. It is as effective as 
a sulfonylurea as monotherapy (when used alone it rarely causes 
hypoglycaemia) and is synergistic in combination with sulfonylurea therapy. 
Metformin also promotes weight loss and decreases lipid levels. Unlike 
phenformin, metformin rarely causes severe lactic acidosis. GI side effects 
are common, but often transient, and may be prevented if the drug is taken 
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with meals and if the dosage is gradually increased ( by 500 mg/week up to 
2.5 g). Metformin is contraindicated in patients with kidney and liver 
diseases or alcoholism. It is also contraindicated in patients with lactic 
acidosis  and should be withheld during acute hospitalization in most 
patients. [34] 
 
 
1.8.2.3  Acarbose 
 
Acarbose is an α-glucosidase inhibitor that competitively inhibits 
hydrolysis of oligo- and monosaccharides. This delays carbohydrate 
digestion in the small intestine and subsequent absorption, resulting in less 
postprandial elevation of blood glucose levels. Because its mechanism of 
action differs from that of other oral hypoglycemics, it can be used in 
combination therapy with other oral agents. GI side effects are very 
common, but often transient. The drug must be taken with meals, and the 
dosage should be gradually increased from 25 mg up to 50 or 100 mg with 
each meal. [34] 
 
 
1.8.2.4  Thiazolidinediones 
 
Thiazolidinediones are the insulin-sensitizer drugs that improve 
insulin sensitivity in skeletal muscle and suppress hepatic glucose output. 
The only such drug available in the USA is troglitazone. It has been recently 
approved for use in the treatment of type II diabetes mellitus patients 
requiring insulin and has moderate effects on decreasing plasma glucose and 
triglyceride levels. This drug is administered once a day and has potentially 
idiosyncratic hepatotoxicity. Patients should be instructed to decrease their 
daily insulin dosage with the initiation of therapy. [34] 
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1.9  Body Weight and Diabetes 
 
 
The link between excess body weight and Type 2 diabetes is 
indisputable. The incidence of diabetes is on the rise around the world and is 
directly linked to the rate of weight gain globally. [4] 
Indeed, being obese and gaining weight increases the risk of 
developing Type 2 diabetes more than ninetyfold. For this reason, both the 
American Heart Association and the European diabetes associations 
recommend that people who have been diagnosed with diabetes lose weight 
to reach a healthy body weight (i.e., a Body Mass Index, BMI of 25 or less). 
[4] 
Currently, about 8% of U.S. adults have been diagnosed with Type 2 
diabetes and most are overweight. According to the Centres for Disease 
Control and Prevention (CDC), 85.2% of people diagnosed with diabetes are 
overweight with a BMI greater than 25 and 54.8% are obese with a BMI 
over 30. People with diabetes who are also obese are more likely to have 
poorer control over their blood sugars than those who are not overweight, 
and they are likely to have more problems with high blood pressure and 
elevated cholesterol levels. [5] 
The combination of excess weight and diabetes is also associated with a 
greater risk for cardiovascular disease and developing complications from 
the diabetes, such as blindness and kidney disease. [17] 
 
The impact of weight loss 
While the statistics may seem grim, there is good news when it comes 
to both the prevention and treatment of Type 2 diabetes. [4] 
Two hallmark trials, one done in Finland and the other in the U.S., 
conclusively found that modest weight losses can make a dramatic 
difference in preventing the development of diabetes among people who are 
at a high risk for developing the disease. [5] 
In the Finnish trial, the risk was reduced by 58 percent, with the 
reduction being directly attributed to lifestyle change. The U.S. study also 
reduced the incidence by 58 percent with a 7% weight loss that was achieved 
with a lifestyle modification program that included diet and physical 
activity. [5] 
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For those who are overweight and already have diabetes, modest 
weight loss can also make a big difference. [4] 
In one study, weight loss was associated with a 25% reduction in total 
mortality, a 28% reduction in deaths due to cardiovascular disease and 
complications from the diabetes. A weight loss of 20-29 pounds was linked 
with the greatest benefit. [4] 
1.9.1  The Body Mass Index 
Body mass index, BMI, is a measurement that evaluates the 
relationship between body weight and height. While BMI is not a direct 
measure of excess body fat, it is the recommended method to diagnose 
overweight and obesity. Because it expresses the weight-height relationship, 
BMI provides a more accurate measure than body weight alone. [6] 
The formula for calculating BMI uses weight in kilograms and height in 
meters: BMI (kg/m2) = Weight (kg) † Height (m) 2; or weight in pounds 
and height in inches: BMI (lb/in2) = Weight (lb) † Height (in) 2*703 [6] 
 
Definitions of overweight, obesity 
Over 50 healthcare organizations around the world, including the 
National Institutes of Health, use the same BMI standards to define adult 
overweight and obesity. [4] 
 
BMI is used as the standard to diagnose overweight and obesity 
because there are so many studies that show a link between BMI, the risk of 
several diseases and death. 
 
Table 1.  Body Mass Index 
 
Definition BMI 
Overweight 25-29.9  
Obese 30-39.9  
Morbidly Obese 40+  
 
Resource: Diabetes, Diet and Nutrition 
http://www.healthnet.com/dandn.htm. 
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As BMI increases, so does the risk for several conditions, including 
 Diabetes  
 Cardiovascular disease  
 Stroke  
 Hypertension  
 Gallbladder disease  
 Osteoarthritis  
 Sleep apnea  
 Some cancers  
 Premature death  
 
While the links between BMI and disease risk is clear, it is important 
to remember that it is only one of several disease risk factors. In other 
words, BMI cannot tell an individual that he or she will get a disease, only 
that his or her risk of developing the disease is increased. [6] 
BMI has some limitations. It tends to overestimate body fat in people 
who are very muscular and underestimate body fat in people who are highly 
sedentary. BMI also doesn't show where the body fat is located. Abdominal 
fat carries the greatest health risk. [5] 
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II.   RESULTS 
 
 
 
 
2.1 National Institute for Health And Clinical 
Excellence ( NICE) 
 
 
 The following guidance is evidence-based. This guidance represents 
the view of the National Institute for Health and Clinical Excellence, which 
was arrived at after carefull consideration of the evidence available. 
 
 
 
2.1.1  Type 1 Diabetes: diagnosis and management of type 1 
diabetes in children, young people and adults according NICE 
guidelines. 
 
 
 
2.1.1.1  Key priorities for implementation: children and young people 
Management from diagnosis:  
 
Children and young people with type 1 diabetes should be offered an 
ongoing integrated package of care by a multidisciplinary paediatric diabetes 
care team. To optimise the effectiveness of care and reduce the risk of 
complications, the diabetes care team should include members with 
appropriate training in clinical, educational, dietetic, lifestyle, mental health 
and foot care aspects of diabetes for children and young people. [8] 
At the time of diagnosis, children and young people with type 1 
diabetes should be offered home-based or inpatient management according 
to clinical need, family circumstances and wishes, and residential proximity 
to inpatient services. Home-based care with support from the local paediatric 
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diabetes care team (including 24-hour telephone access to advice) is safe and 
as effective as inpatient initial management. [8] 
 
Education 
 
Children and young people with type 1 diabetes and their families 
should be offered timely and ongoing opportunities to access information 
about the development, management and effects of type 1 diabetes. The 
information provided should be accurate and consistent and it should support 
informed decision-making. [8] 
 
Monitoring glycaemic control 
 
Children and young people with type 1 diabetes and their families 
should be informed that the target for long-term glycaemic control is an 
HbA1c level of less than 7.5% without frequent disabling hypoglycaemia 
and that their care package should be designed to attempt to achieve this. [8] 
 
Diabetic ketoacidosis 
 
Children and young people with diabetic ketoacidosis should be 
treated according to the guidelines published by the British Society for 
Paediatric Endocrinology and Diabetes. [8] 
 
Screening for complications and associated conditions 
 
Children and young people with type 1 diabetes should be offered 
screening for: 
• coeliac disease at diagnosis and at least every 3 years thereafter until 
transfer to adult services. 
• thyroid disease at diagnosis and annually thereafter until transfer to adult 
services. 
• retinopathy annually from the age of 12 years. 
• microalbuminuria annually from the age of 12 years. 
• blood pressure annually from the age of 12 years. [8] 
 
Psychosocial support 
 
Children and young people with type 1 diabetes and their families 
should be offered timely and ongoing access to mental health professionals 
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because they may experience psychological disturbances (such as anxiety, 
depression, behavioural and conduct disorders and family conflict) that can 
impact on the management of diabetes and well-being. [8] 
 
 
 
2.1.1.2  Key messages: adults 
 
The Guideline Development Group reviewed the recommendations 
and summarised these key messages for implementation. [8] 
 
Patient-centred care 
 
The views and preferences of individuals with type 1 diabetes should 
be integrated into their healthcare. Diabetes services should be organised, 
and staff trained, to allow and encourage this. [8] 
 
Multidisciplinary team approach 
 
The range of professional skills needed for delivery of optimal advice 
to adults with diabetes should be provided by a multidisciplinary team. Such 
a team should include members having specific training and interest to cover 
the following areas of care: 
• education/information giving 
• nutrition 
• therapeutics 
• identification and management of complications 
• foot care 
• counselling 
• psychological care. [8] 
 
Education for adults with diabetes 
 
Culturally appropriate education should be offered after diagnosis to 
all adults with type 1 diabetes (and to those with significant input into the 
diabetes care of others). It should be repeated as requested and according to 
annual review of need. [8] 
This should encompass the necessary understanding, motivation, and 
skills to manage appropriately: 
• blood glucose control (insulin, self-monitoring, nutrition) 
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• arterial risk factors (blood lipids, blood pressure, smoking) 
• late complications (feet, kidneys, eyes, heart). [8] 
 
Blood glucose control 
Blood glucose control should be optimised towards attaining DCCT-
harmonised HbA1c targets for prevention of microvascular disease (less than 
7.5%) and, in those at increased risk, arterial disease (less than or equal to 
6.5%) as appropriate, while taking into account: 
• the experiences and preferences of the insulin user, in order to avoid 
hypoglycaemia. [8] 
• the necessity to seek advice from professionals knowledgeable about the 
range of available meal-time and basal insulins and about optimal 
combinations thereof, and their optimal use. [8] 
 
Arterial risk-factor control 
 
Adults with type 1 diabetes should be assessed for arterial risk at 
annual intervals. Those found to be at increased risk should be managed 
through appropriate interventions and regular review. [8] 
Note should be taken of: 
• microalbuminuria, in particular. 
• the presence of features of the metabolic syndrome. 
• conventional risk factors (family history, abnormal lipid profile, raised 
blood pressure, smoking). [8] 
 
Late complications 
 
Adults with type 1 diabetes should be assessed for early markers and 
features of eye, kidney, nerve, foot and arterial damage at annual intervals. 
According to assessed need, they should be offered appropriate interventions 
and/or referral in order to reduce the progression of such late complications 
into adverse health outcomes affecting quality of life. [8] 
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2.1.2  NICE Diet guidelines for Type 1 Diabetes 
 
 Children and young people with type 1 diabetes should be offered 
appropriate dietetic support to help optimise body weight and 
glycaemic control. 
 Children and young people with type 1 diabetes and their families 
should be informed that they have the same basic nutritional 
requirements as other children and young people. The food choices of 
children and young people should provide sufficient energy and 
nutrients for optimal growth and development, with total daily energy 
intake being distributed as follows: 
• carbohydrates – more than 50% 
• protein – 10–15% 
• fat – 30–35%. [8] 
 
The consumption of five portions of fruit and vegetables per day is 
also recommended. Neonates, infants and pre-school children require 
individualised dietary assessment to determine their energy needs. [8] 
 Children and young people with type 1 diabetes should be encouraged 
to develop a good working knowledge of nutrition and how it affects 
their diabetes. 
 Children and young people with type 1 diabetes and their families 
should be informed of the importance of healthy eating in reducing 
the risk of cardiovascular disease (including foods with a low 
glycaemic index, fruit and vegetables, and types and amounts of fats), 
and means of making appropriate nutritional changes in the period 
after diagnosis and according to need and interest at intervals 
thereafter. 
 Children and young people with type 1 diabetes should be encouraged 
to consider eating a bedtime snack. The nutritional composition and 
timing of all snacks should be discussed with the diabetes care team. 
 Children and young people using multiple daily injection regimens 
should be offered education about insulin and dietary management as 
part of their diabetes care package, to enable them to adjust their 
insulin dose to reflect their carbohydrate intake. 
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 Children and young people with type 1 diabetes should be offered 
education about the practical problems associated with fasting and 
feasting. [8] 
 
 
 
 
2.1.3  Treatment of type 1 diabetes 
 
 
2.1.3.1  NICE recommendations for treatment of Type 1 
Diabetes in children 
 
 
Insulin regimens 
 
While the insulin regimen should be individualised for each patient, 
three basic types of insulin regimen can be considered. [8] 
One, two or three insulin injections per day: these are usually 
injections of short-acting insulin or rapid-acting insulin analogue mixed with 
intermediate-acting insulin. The insulin preparations may be mixed by the 
patient at the time of injection. [8] 
Multiple daily injection regimen: the person has injections of short 
acting insulin or rapid-acting insulin analogue before meals, together with 
one or more separate daily injections of intermediate-acting insulin or long-
acting insulin analogue. [8] 
Continuous subcutaneous insulin infusion (insulin pump therapy): 
A programmable pump and insulin storage reservoir that gives a 
regular or continuous amount of insulin (usually in the form of a rapid-
acting insulin analogue or short-acting insulin) by a subcutaneous needle or 
cannula. [8] 
 Pre-school and primary school children with type 1 diabetes should be 
offered the most appropriate individualised regimens to optimise their 
glycaemic control. 
 Young people with type 1 diabetes should be offered multiple daily 
injection regimens to help optimise their glycaemic control. 
 Multiple daily injection regimens should be offered only as part of a 
package of care that involves continuing education, dietary 
management, instruction on the use of insulin delivery systems and 
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blood glucose monitoring, emotional and behavioural support, and 
medical, nursing and dietetic expertise in paediatric diabetes, because 
this improves glycaemic control. 
 Children and young people using multiple daily injection regimens 
should be informed that they may experience an initial increase in the 
risk of hypoglycaemia and short-term weight gain. 
 Children and young people with type 1 diabetes and their families 
should be informed about strategies for the avoidance and 
management of hypoglycaemia. 
 Young people who do not achieve satisfactory glycaemic control with 
multiple daily injection regimens should be offered additional support 
and, if appropriate, alternative insulin therapy (once-, twice- or three-
times daily mixed insulin regimens or continuous subcutaneous 
insulin infusion using an insulin pump). 
 Young people with type 1 diabetes who have difficulty adhering to 
multiple daily injection regimens should be offered twice-daily 
injection regimens. 
 Continuous subcutaneous insulin infusion (or insulin pump therapy) is 
recommended as an option for people with type 1 diabetes provided 
that: multiple-dose insulin therapy (including, where appropriate, the 
use of insulin glargine) has failed; and those receiving the treatment 
have the commitment and competence to use the therapy effectively. 
 Continuous subcutaneous insulin infusion therapy should be initiated 
only by a trained specialist team, which should normally comprise a 
physician with a specialist interest in insulin pump therapy, a diabetes 
specialist nurse and a dietitian. 
 All individuals beginning continuous subcutaneous insulin infusion 
therapy should be provided with specific training in its use. Ongoing 
support from a specialist team should be available, particularly in the 
period immediately following the initiation of continuous 
subcutaneous insulin infusion. It is recommended that specialist teams 
should agree a common core of advice appropriate for continuous 
subcutaneous insulin infusion users. 
 Established users of continuous subcutaneous insulin infusion therapy 
should have their insulin management reviewed by their specialist 
team so that a decision can be made about whether a trial or a switch 
to multiple-dose insulin incorporating insulin glargine would be 
appropriate. [8] 
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Insulin preparations 
 
Different types of insulin are available for use in the insulin regimens 
for type 1 diabetes. They work for different lengths of time when injected 
subcutaneously. The appropriate insulin with its particular absorption profile 
should be matched to the person‟s needs in an attempt to obtain normal to 
near-normal blood glucose control. [8] 
The main categories of insulin are: 
• rapid-acting insulin analogues: these aim to work like the insulin 
normally produced to cope with a meal; they have an onset of action of 
approximately 15 minutes and a duration of action of 2–5 hours. 
• short-acting insulins: these work more slowly than rapid-acting insulin 
analogues; they have an onset of action of 30–60 minutes and a duration of 
action of up to 8 hours. 
• intermediate-acting insulins: these have an onset of action of 
approximately 1–2 hours, maximal effects between 4 and 12 hours and a 
duration of action of 16–35 hours. 
• long-acting insulin analogues: these can last for a longer period than 
intermediate-acting insulins; they are normally used once a day and achieve 
a steady-state level after 2–4 days to produce a constant level of insulin. [8] 
A biphasic insulin is a mixture of rapid-acting insulin analogue or 
short-acting insulin together with intermediate-acting insulin. [8] 
 
 Children and young people with type 1 diabetes should be offered the 
most appropriate insulin preparations (rapid-acting insulin analogues, 
short-acting insulins, intermediate-acting insulins, long-acting insulin 
analogues or biphasic insulins) according to their individual needs and 
the instructions in the patient information leaflet supplied with the 
product, with the aim of obtaining an HbA1c level of less than 7.5% 
without frequent disabling hypoglycaemia and maximising quality of 
life. 
 Children and young people with type 1 diabetes using multiple daily 
insulin regimens should be informed that injection of rapid-acting 
insulin analogues before eating (rather than after eating) reduces post-
prandial blood glucose levels and thus helps to optimise blood glucose 
control. 
 For pre-school children with type 1 diabetes it may be appropriate to 
use rapid-acting insulin analogues shortly after eating (rather than 
before eating) because food intake can be unpredictable. 
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 Children and young people with type 1 diabetes who use insulin 
preparations containing intermediate-acting insulin should be 
informed that these preparations should be mixed before use 
according to the instructions in the patient information leaflet supplied 
with the product. [8] 
 
 
Methods of delivering insulin 
 
 Children and young people with type 1 diabetes should be offered a 
choice of insulin delivery systems that takes account of their insulin 
requirements and personal preferences. 
 Children and young people with type 1 diabetes using insulin injection 
regimens should be offered needles that are of an appropriate length 
for their body fat (short needles are appropriate for children and 
young people with less body fat; longer needles are appropriate for 
children and young people with more body fat). [8] 
 
Non-insulin agents(oral antidiabetic drugs) 
 
 Children and young people with type 1 diabetes should not be offered 
acarbose or sulphonylureas (glibenclamide, gliclazide, glipizide, 
tolazamide or glyburide) in combination with insulin because they 
may increase the risk of hypoglycaemia without improving glycaemic 
control. 
 Metformin in combination with insulin is suitable for use only within 
research studies because the effectiveness of this combined treatment 
in improving glycaemic control is uncertain. [8] 
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2.1.3.2  NICE Recommendations for treatment of Type 1 
Diabetes in adults 
 
 
Insulin regimens 
 
 Adults with type 1 diabetes should have access to the types 
(preparation and species) of insulin they find allow them optimal well-
being. 
 Cultural preferences need to be discussed and respected in agreeing 
the insulin regimen for a person with type 1 diabetes. 
 Multiple insulin injection regimens, in adults who prefer them, should 
be used as part of an integrated package of which education, food and 
skills training should be integral parts. 
 Appropriate self-monitoring and education should be used as part of 
an integrated package to help achieve optimal diabetes outcomes. 
 Meal-time insulin injections should be provided by injection of 
unmodified („soluble‟) insulin or rapid-acting insulin analogues before 
main meals. 
 Rapid-acting insulin analogues should be used as an alternative to 
meal-time unmodified insulin: 
• where nocturnal or late inter-prandial hypoglycaemia is a problem. 
• in those in whom they allow equivalent blood glucose control without use 
of snacks between meals and this is needed or desired. 
 Basal insulin supply (including nocturnal insulin supply) should be 
provided by the use of isophane (NPH) insulin or long-acting insulin 
analogues (insulin glargine). Isophane (NPH) insulin should be given 
at bedtime. If rapid-acting insulin analogues are given at meal times or 
the midday insulin dose is small or lacking, the need to give isophane 
(NPH) insulin twice daily (or more often) should be considered. 
 Long-acting insulin analogues (insulin glargine) should be used when: 
• nocturnal hypoglycaemia is a problem on isophane (NPH) insulin. 
• morning hyperglycaemia on isophane (NPH) insulin results in difficult 
daytime blood glucose control. 
• rapid-acting insulin analogues are used for meal-time blood glucose 
control. 
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 Twice-daily insulin regimens should be used by those adults who 
consider number of daily injections an important issue in quality of 
life. 
• Biphasic insulin preparations (pre-mixes) are often the preparations of 
choice in this circumstance. 
• Biphasic rapid-acting insulin analogue pre-mixes may give an advantage to 
those prone to hypoglycaemia at night. 
Such twice daily regimens may also help: 
• those who find adherence to their agreed lunch-time. insulin injection 
difficult. 
• adults with learning difficulties who may require assistance from others. 
 Adults whose nutritional and physical activity patterns vary 
considerably from day to day, for vocational or recreational reasons, 
may need careful and detailed review of their self-monitoring and 
insulin injection regimen(s). This should include all the appropriate 
preparations, and consideration of unusual patterns and combinations. 
 For adults undergoing periods of fasting or sleep following eating 
(such as during religious feasts and fasts or after night-shift work), a 
rapid-acting insulin analogue before the meal (provided the meal is 
not prolonged) should be considered. 
 For adults with erratic and unpredictable blood glucose control 
(hyper- and hypoglycaemia at no consistent times), rather than a 
change in a previously optimised insulin regimen, the following 
should be considered: 
• resuspension of insulin and injection technique. 
• injection sites. 
• self-monitoring skills. 
• knowledge and self-management skills. 
• nature of lifestyle. 
• psychological and psychosocial difficulties. 
• possible organic causes such as gastroparesis. 
 Continuous subcutaneous insulin infusion (or insulin pump therapy) is 
recommended as an option for people with type 1 diabetes provided 
that: multiple-dose insulin therapy (including, where appropriate, the 
use of insulin glargine) has failed; and those receiving the treatment 
have the commitment and competence to use the therapy effectively. 
 Partial insulin replacement to achieve blood glucose control targets 
(basal insulin only, or just some meal-time insulin) should be 
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considered for adults starting insulin therapy, until such time as islet 
B-cell deficiency progresses further. 
 Clear guidelines and protocols („sick-day rules‟) should be given to all 
adults with type 1 diabetes to assist them in adjusting insulin doses 
appropriately during intercurrent illness. 
 Oral glucose-lowering drugs should generally not be used in the 
management of adults with type 1 diabetes. [8] 
 
Insulin delivery 
 
 Adults with diabetes who inject insulin should have access to the 
insulin injection delivery device they find allows them optimal well-
being, often using one or more types of insulin injection pen. 
 Adults with type 1 diabetes who have special visual or psychological 
needs should be provided with injection devices or needle-free 
systems that they can use independently for accurate dosing. 
 Insulin injection should be made into the deep subcutaneous fat. To 
achieve this, needles of a length appropriate to the individual should 
be made available. 
 Adults with type 1 diabetes should be informed that the abdominal 
wall is the therapeutic choice for meal-time insulin injections. 
 Adults with type 1 diabetes should be informed that extended-acting 
suspension insulin, for example isophane (NPH) insulin, may give a 
longer profile of action when injected into the subcutaneous tissue of 
the thigh rather than the arm or abdominal wall. 
 Adults with diabetes should be recommended to use one anatomical 
area for the injections given at the same time of day, but to move the 
precise injection site around in the whole of the available skin within 
that area. 
 Adults with diabetes should be provided with suitable containers for 
the collection of used needles. Arrangements should be available for 
the suitable disposal of these containers. 
 The injection-site condition should be checked annually and if new 
problems with blood glucose control occur. [8] 
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2.1.4  NICE guidance for non-pharmacological management 
of Type 2 Diabetes 
 
 
The following guidance is based on the best available evidence. It 
describes in details the methods and the evidence used to develop the 
guidance. 
 
 
Dietary advice 
 
 Provide all people with diabetes with individualised nutritional advice 
as part of ongoing management from someone with specific expertise 
in nutrition.  
 Provide that advice in a form sensitive to the individual's needs, 
culture, and beliefs, being sensitive to their willingness to change, and 
the effects on their quality of life.  
 Place particular emphasis on general population dietetic measures 
(include carbohydrate from fruits, vegetables, whole-grains, and 
pulses [and thus high fibre and low glycaemic index], the inclusion of 
low fat dairy products and oily fish, and control of saturated and trans 
fatty acid intake) when providing advice to people with diabetes.  
 Integrate the advice given into the individual's overall diabetes 
management plan, including other aspects of lifestyle modification 
such as increasing physical activity.  
 Target, for the overweight, an initial body weight loss of 5-10%, while 
remembering that any weight loss may be of benefit, and larger 
degrees of weight loss in the longer term will have advantageous 
metabolic impact.  
 Individualise carbohydrate and alcohol recommendations, and meal 
pattern, in particular for people using insulin or insulin secretagogues 
aiming to reduce the risk of hypoglycaemia.  
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 Advise that limited use of sucrose-containing foods is allowable when 
substituted for other carbohydrate in the meal plan but with care to 
avoid excess energy intake. 
  Discourage the use of foods marketed specifically for people with 
diabetes.  
 When patients are admitted to hospital as in-patients or to any other 
institutions, implement a meal planning system that provides 
consistency in the carbohydrate content of meals. [8] 
 
 
 
 
 
 
2.1.5  NICE guidance for the pharmacotherapy of Type 2 
Diabetes 
 
2.1.5.1  Oral glucose control therapies (1): metformin, insulin 
secretagogues, and acarbose  
1. Metformin  
 Begin metformin in people who are overweight or obese for their 
ethnic group and whose blood glucose control is inadequate when 
using lifestyle interventions (nutrition and exercise) alone.  
 Consider metformin as an option for first-line glucose-lowering 
therapy in people who are not overweight.  
 Continue metformin when blood glucose control remains or becomes 
inadequate and other oral glucose-lowering medication (usually a 
sulfonylurea) is added.  
 Step up metformin therapy gradually over weeks to minimise risk of 
gastro-intestinal (GI) side effects. Consider a trial of extended-
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absorption metformin tablets, where GI tolerability prevents 
continuation of metformin therapy.  
 Review metformin dose when serum creatinine >130 micromol/litre 
or estimated glomerular filtration rate (eGFR) <45 ml/min/1.73 m
2
.  
 • Stop metformin if serum creatinine >150 micromol/litre or 
eGFR <30 ml/min/1.73 m
2
.  
 • Prescribe metformin with caution in those at risk of sudden 
deterioration of kidney function, or at risk of a decline of eGFR 
to <45 ml/min/1.73 m
2
.  
 The benefits of metformin therapy should be discussed with people 
who have type 2 diabetes and mild to moderate liver dysfunction or 
cardiac impairment so that:  
 due consideration is given to the cardiovascular protective effects of 
the drug  
 an informed patient decision is made regarding whether to continue or 
stop the metformin therapy. [8] 
 
2. Insulin secretagogues  
 Consider a sulfonylurea as an option for first-line glucose-lowering 
therapy in people who are not overweight:  
 • where metformin is not tolerated or is contraindicated  
 • where a rapid response to therapy is required because of 
hyperglycaemic symptoms.  
 Use a sulfonylurea as second-line therapy when blood glucose control 
remains or becomes inadequate on metformin.  
 Continue a sulfonylurea when blood glucose control remains or 
becomes inadequate and other oral glucose-lowering medication is 
added.  
 Prescribe a sulfonylurea with low acquisition cost (but not 
glibenclamide) where an insulin secretagogue is indicated as above.  
 In people where drug concordance is problematic a once daily long-
acting sulfonylurea should be offered.  
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 Educate people being treated with an insulin secretagogue about the 
risk of hypoglycaemia, in particular those with renal impairment. [8] 
 
3. Rapid-acting insulin secretagogues  
 Consider offering rapid-acting insulin secretagogues to people with 
non-routine daily lifestyle patterns to assist in attaining glucose 
control to their individual target. [8] 
 
4. Acarbose  
 Consider acarbose as an alternative glucose-lowering therapy in 
people unable to use other oral glucose-lowering medications. [8] 
 
2.1.5.2  Oral glucose control therapies (2): other oral agents and 
exenatide         
1. PPAR-γ agonists  
 Consider, after discussion with the person with diabetes, a PPAR-γ 
agonist (thiazolidinedione) when glucose concentrations are not 
adequately controlled (to HbA
1c 
of <7.5% or other higher level 
individually agreed), adding it to:  
 • the combination of metformin and a sulfonylurea where 
insulin is contraindicated or is likely to be poorly tolerated, for 
example because of the nature of employment (for example, 
HGV licence holders), needle phobia, or other personal issues, 
or:  
 • a sulfonylurea where metformin is not tolerated, or  
 • metformin as an alternative to a sulfonylurea where 
occupation or other issues make the hypoglycaemia risk with 
sulfonylureas of particular significance.†  
 Warn people prescribed a thiazolidinedione about the possibility of 
development of significant oedema, and the action to take should that 
occur.  
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 PPAR-γ agonists should not be commenced or continued in people 
who have evidence of heart failure.  
 Prescribe the thiazolidinedione which has the lower acquisition cost, 
where such a medication is indicated as above. [8] 
 
2. GLP-1 mimetics - exenatide  
 Exenatide is not recommended for routine use for people with type 2 
diabetes.  
 Exenatide should only be considered for people with type 2 diabetes 
who have all of the following:  
 • a body mass index over 35.0 kg/m2  
 • specific problems of a psychological, biochemical, or physical 
nature arising from high body weight  
 • inadequate blood glucose control (HbA
1c 
>7.5 %) on 
conventional oral agent therapy after trial of metformin and 
sulfonylurea, and  
 • where other high cost medications such as thiazolidinediones 
or insulin injection therapy would otherwise be started.  
 Continue exenatide therapy only if a useful metabolic response (at 
least 1.0 % HbA1c reduction in 6 months and a weight loss of at least 
5 % at 1 year) is obtained and maintained. [8] 
 
 
 
2.1.5.3  Type 2 Diabetes: newer agents for blood glucose control in type 
2 diabetes 
 
Incretin enhancers (DPP-4 inhibitors)  
 Sitagliptin. Sitagliptin has UK marketing authorisation for use in 
patients with type 2 diabetes mellitus as oral therapy to improve 
glycaemic control in combination with:  
 67 
 1. metformin if diet and exercise plus metformin do not provide 
adequate glycaemic control.  
2.a sulphonylurea, in patients with insufficient glycaemic 
control despite the maximum tolerated dose of a sulphonylurea 
and for whom metformin is inappropriate because of 
contraindications or intolerance. 
3.a sulphonylurea and metformin, in patients with insufficient 
glycaemic control  
4.a thiazolidinedione, in patients with insufficient glycaemic 
control and for whom the use of a thiazolidinedione is 
appropriate.  
 Vildagliptin. Vildagliptin has UK marketing authorisation for use in 
the treatment of type 2 diabetes mellitus as dual oral therapy in 
combination with:  
1.metformin, in patients with insufficient glycaemic control 
despite the maximum tolerated dose of monotherapy with 
metformin.  
2.sulphonylurea, in patients with insufficient glycaemic control 
despite the maximum tolerated dose of a sulphonylurea and for 
whom metformin is inappropriate because of contraindications 
or intolerance.  
3. thiazolidinedione, in patients with insufficient glycaemic 
control and for whom the use of a thiazolidinedione is 
appropriate. [8] 
 
 
Incretin mimetics (GLP-1 analogues)  
 Exenatide. Exenatide currently has UK marketing authorisation for 
the treatment of type 2 diabetes mellitus in combination with 
metformin and/or sulphonylureas in people who have insufficient 
glycaemic control on the maximum tolerated doses of these oral 
therapies. It is administered as a subcutaneous injection.  
 Liraglutide. Liraglutide does not yet have UK marketing 
authorisation. It has been studied in phase III trials in patients with 
type 2 diabetes who have been treated with oral glucose-lowering 
medications (metformin and a sulphonylurea). These studies have 
examined the use of liraglutide as monotherapy and as combination 
with metformin, sulphonylureas, metformin and a sulphonylurea, and 
metformin and a thiazolidinedione. Liraglutide has also been studied 
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in combination with a sulphonylurea, and in combination with a 
thiazolidinedione. [8] 
 
 
Thiazolidinediones  
 Pioglitazone. Pioglitazone is administered orally and has UK 
marketing authorisation for use:  
1.as monotherapy in people (particularly those who are 
overweight) who have insufficient glycaemic control from diet 
and exercise, and for whom metformin is inappropriate because 
of contraindications of intolerance.  
2.as dual oral therapy in combination with metformin in people 
(particularly those who are overweight) with insufficient 
glycaemic control despite the maximum tolerated dose of 
monotherapy with metformin.  
3.as dual oral therapy in combination with a sulphonylurea, 
only in people who show intolerance to metformin or for whom 
metformin is contraindicated, and who have insufficient 
glycaemic control despite the maximum tolerated dose of 
monotherapy with a sulphonylurea.  
4.as triple therapy in combination with metformin and a 
sulphonylurea, in people (particularly those who are 
overweight) with insufficient glycaemic control despite dual 
oral therapy.  
5.in combination with insulin in people with type 2 diabetes 
with insufficient glycaemic control on insulin for whom 
metformin is inappropriate because of contraindications or 
intolerance.  
 Pioglitazone/metformin combination. This combination product is 
administered orally and is indicated for the treatment of type 2 
diabetes, particularly in people who are overweight, and who are 
unable to achieve sufficient glycaemic control at the maximum 
tolerated dose of oral metformin alone.  
 Rosiglitazone. Rosiglitazone is indicated for the treatment of type 2 
diabetes and has UK marketing authorisation for use:  
1.as oral monotherapy in people (particularly those who are 
overweight) who have insufficient glycaemic control from diet 
and exercise for whom metformin is inappropriate because of 
contraindications or intolerance.  
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2.as dual oral therapy in combination with metformin in people 
(particularly those who are overweight) with insufficient 
glycaemic control despite the maximum tolerated dose of 
monotherapy with metformin.  
3.as dual oral therapy in combination with a sulphonylurea, 
only in people who show intolerance to metformin or for whom 
metformin is contraindicated, and who have insufficient 
glycaemic control despite the maximum tolerated dose of 
monotherapy with a sulphonylurea.  
4.as triple therapy in combination with metformin and a 
sulphonylurea, in people (particularly those who are 
overweight) with insufficient glycaemic control despite dual 
oral therapy.  
 Rosiglitazone/metformin combination. This combination has UK 
marketing authorisation for oral use in people for whom the maximum 
tolerated dose of oral metformin alone does not provide sufficient 
glycaemic control. It also has UK marketing authorisation for use as 
triple oral therapy with a sulphonylurea in people with insufficient 
glycaemic control despite dual oral therapy with the maximum 
tolerated dose of metformin and a sulphonylurea. [8] 
 
 
Long-acting recombinant human insulin analogues  
 Insulin detemir. Insulin detemir is indicated for the treatment of 
diabetes mellitus, including use with oral hypoglycaemia agents. It is 
administered via subcutaneous injection.  
 Insulin glargine. Insulin glargine is indicated for the treatment of 
diabetes mellitus, including use with oral hypoglycaemia agents. It is 
administered via subcutaneous injection. [8] 
 
 
 
 
2.1.5.4  Glucose control: insulin therapy  
1. Oral agent combination therapy with insulin  
 When commencing basal insulin therapy in a person with type 2 
diabetes:  
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 • continue metformin and sulfonylureas (α-glucosidase 
inhibitors if used may also be continued)  
 • review use of the sulfonylurea if hypoglycaemia occurs.  
 When commencing pre-mix insulin therapy (or meal-time+basal 
insulin regimens) in a person with type 2 diabetes:  
 • continue metformin  
 • continue sulfonylureas initially but review and discontinue if 
hypoglycaemia occurs.  
 Combined pioglitazone-insulin therapy should be considered:  
 • in people who have previously shown a marked glucose-
lowering response to thiazolidinedione therapy  
 • in those on high dose insulin therapy with inadequate blood 
glucose control.  
Warn to discontinue the thiazolidinedione if significant fluid 
retention develops. [8] 
 
     2. Insulin therapy  
 In people with type 2 diabetes when other measures have failed to 
achieve blood glucose control the benefits and risks of insulin therapy 
should be discussed. Insulin therapy should be commenced if agreed.  
 Insulin therapy should be commenced using a structured programme 
employing active insulin dose titration founded on:  
 • structured education  
 • continuing telephone support   
 • frequent self-monitoring  
• dose titration to target  
 • dietary understanding  
 • management of hypoglycaemia  
 • management of acute changes in plasma glucose control  
 • with support from an appropriately trained and experienced 
health-care professional.  
 Insulin therapy should be initiated from a choice of a number of 
insulin types and regimens. 
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  • Begin with human NPH insulin, given at bed-time or twice 
daily according to need.  
 • Insulin glargine is not recommended for routine use for people 
with type 2 diabetes who require insulin therapy. Insulin 
glargine treatment should be considered only for those people 
with type 2 diabetes who require insulin therapy and who fall 
into one of the following categories:  
 − Those who require assistance from a carer or healthcare 
professional to administer their insulin injections.  
 − Those whose lifestyle is significantly restricted by recurrent 
symptomatic hypoglycaemic episodes.  
 − Those who would otherwise need twice-daily basal insulin 
injections in combination with oral antidiabetic drugs.  
 • Consider starting with biphasic insulin (pre-mix) regimens 
once or twice daily, the latter in particular where HbA
1c 
is 
elevated above 9.0%.  
 • Consider insulin analogue-based pre-mixes instead of human 
insulin pre-mixes where:  
 − immediate injection before a meal is preferred,  
 − if hypoglycaemia is a problem, or where  
 − post-prandial blood glucose excursions are marked.  
 
 
 A trial of a long-acting insulin analogue (insulin glargine) should be 
offered where people starting NPH insulin suffer significant 
nocturnal hypoglycaemia.  
 Monitor people using basal insulin regimens (NPH or a long-acting 
insulin analogue [insulin glargine] for the need for addition of meal-time 
insulin (or use of pre-mix insulins). Where blood glucose control remains 
inadequate (not to agreed target levels without problematic 
hypoglycaemia) move to a more intensive meal-time plus basal insulin 
regimen, including an analogue-based regimen.  
 Monitor people using pre-mixed insulin once or twice a day for the need 
of a further pre-prandial injection or eventually changing to a meal-time 
plus basal insulin regimen, including an analogue-based regimen where 
blood glucose control remains inadequate. [8] 
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2.2  Diabetes mellitus in Cyprus 
 
  
The main goal of the following description is to give the general 
situation concerning diabetes mellitus in Cyprus, including: epidemiological 
facts, general management of diabetes in clinics, the role of the Cyprus 
Diabetic Association, the role of the state, measures taken for prevention of 
the disease, reimbursement of insulin and other antidiabetics. 
 
 
The present situation regarding Diabetes Care in Cyprus is that all 
Government General Hospitals have a diabetes clinic.  All the doctors are 
internists with special interest in diabetes or endocrinology.  There are four 
diabetes clinics for children with diabetes.  In March 2000, the Ministry of 
Health organised a seminar about the care of diabetic patients.  About 26 
nurses were trained in diabetes issues.  There are four dieticians working in 
the Government Sector but no Chiropodists.  There are laboratory and 
ophthalmology services and services for pregnant women, children and 
elderly people with diabetes.  A National Diabetic Retinopathy Screening 
Programme, using digital imaging and grading will be initiated by the 
Department of Health and Public Health Services with a target population of 
all people with diabetes over the age of 12 years. [26] 
It is the policy of the Ministry of Health to develop a National Plan for 
Diabetes Mellitus in Cyprus.  The National Committee will include the 
Ministry of Health, the Ministry of Social Affairs, non-governmental 
organisations, the Diabetes, Medical and Dietetic Associations, 
Pharmaceutical Services and Friends.  Objectives for activities will include 
Public and Professional awareness and primary and secondary prevention. 
[27] 
Primary prevention includes the education of the Cypriot population 
through health promotion (lectures, leaflets), school services and targeted 
activities.  Programmes to prevent type 2 diabetes and other risk factors for 
cardiovascular disease in the population are planned with School Health 
Services and the Ministry of Agriculture.  Other initiatives include lectures 
to women from rural areas, leaflets, healthy eating days, promoting the 
Mediterranean diet in co-operation with local municipalities and non-
governmental organisations. The key non-governmental organisation is the 
 73 
Cyprus Diabetes Organisation, which is involved in the National Co-
ordinating Committee for Diabetes, as well as the Medical Scientific 
Associations.  Education for General Practitioners (Government and Private) 
is provided in a short course about diabetes issues.  The course includes 
prevention and treatment of diabetes and the prevention and treatment of 
complications. [29] 
Secondary prevention is addressed through four clinics for diabetes in 
the Government Hospitals in Nicosia, Limassol, Larnaka and Archbishop 
Makarios III for children with diabetes.  The Ministry of Health and the 
National Co-ordinating Committee for Diabetes are committed to 
establishing a Centre of Excellence for Diabetes, a Programme of 
seminars and lectures to all General Practitioners and four doctors to 
work for a year or more in University Diabetes Clinics.  [19] 
 
 
 
 
 
 
 
 
 
2.2.1  General facts 
 
The objective of the following table is to show the total prevalence of 
diabetes among Greek Cypriots in 2003 and the actions taken from the state 
against the disease. The cost was not estimated precisely. The data were 
taken from the Cyprus Diabetic Association which collected the data from 
the Ministry of Health. 
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Table2.  Prevalence, cost and national plans for diabetes in Cyprus 
 
FACTS  
Estimated prevalence (% of total 
population above 20 years old) 
5.1-10.3% 
Total diabetes prevalent cases 27,700-170,000 
Cost of diabetes (% of total 
healthcare budget) 
Not estimated 
POLICY FRAMEWORK  
National Plan  - 
Guidelines In progress 
Planned Actions Healthcare reforms Diabetes 
National Plan 
Resource: Cyprus Diabetic Association (CDA). www.diabetes.org.cy. 
 
 
2.2.1.1  Incidence/Prevalence of diabetes 
In 2001, the (growing) number of people in Cyprus living with 
diabetes was estimated at more than 60,000 with a further 60,000 
undiagnosed. Comprehensive data is scant for the Republic of Cyprus as, 
until the diabetes register is completed, there are no records. [26] 
The estimated diabetes prevalence was 5.1% in 2003 according to the 
IDF Atlas. According to the Cyprus Diabetes Association, diabetes 
prevalence today is estimated at 10.3%, with more than 70,000 people living 
with diabetes. Furthermore, the WHO predicts that the prevalence of 
diabetes in Cyprus will increase by 74% between 2000 and 2030. [28] 
Diabetes is thought to represent about 2.1% of the disease burden in 
Cyprus and approximately 2.3% of total deaths. These numbers 
underestimate the importance of diabetes because they do not take account 
of diabetes as a secondary cause of death. For example, cardiovascular 
disease, one of the many serious complications associated with diabetes, 
represents 17% of the disease burden in Cyprus, and is estimated to account 
for around 41% of deaths in the country. [2] 
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Obesity is one of the high risk factors for the onset of diabetes and up 
to 23% of 13-17-year olds in Cyprus are obese or overweight. With respect 
to obesity, Cyprus shares second place in the EU with Greece, Italy, and 
Ireland. [26] 
 
 
2.2.1.2  Cost of diabetes care 
Expenditure on health (excluding capital spending) has increased 
during the last ten years, reaching 5.8% of GDP in 2002 against 2.8% in 
1980. It is estimated by the Cyprus Diabetic Association that the annual cost 
of treatment of a person with diabetes in Cyprus is £3,000 per year. The 
growth rate for the last five years is estimated at 2.3%. [27] 
 
2.2.1.3  Government priorities 
Reform of the healthcare sector is currently a high priority for the 
Government of the Republic of Cyprus. The present system has been 
criticised for the fragmentation of services and lack of coordination between 
the public and private health sectors. The Strategic Plan 1999-2003 aimed to 
improve the level of coordination of the two sectors, improve public health 
and preventative activities, create a medical school, encourage medical 
research and create a district level authority for decentralization.  [21] 
On 20 April 2001, the House of Representatives enacted a law for the 
introduction of a National Health Insurance System (NHIS), which is 
currently being implemented and is intended to provide free healthcare at 
the point of delivery. It will be universal as regards population coverage and 
will be financed by contributions from the state, employers, employees, the 
self-employed, pensioners and all those who have non-employment incomes. 
[24] 
As part of these reforms, the Government is also considering the 
development of a national plan for diabetes that is intended to evolve in line 
with the new national healthcare system. [21] 
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2.2.1.4  Policy Framework 
 
In 2003, the “National Coordinating Committee  for Diabetes” 
Committee proposed a “Plan of Action for Diabetes” to the Ministry of 
Health: this is still under discussion. The programme would include the 
creation of a “Diabetes Register”, including an immediate epidemiological 
survey on diabetes prevalence. [27] 
The Government is developing specialised diabetes clinics in hospitals 
throughout Cyprus to be staffed by specialised healthcare professionals. [21] 
 
 
2.2.1.5  Guidelines 
The Health Ministry is currently finalising guidelines for health 
professionals, particularly in the newly-created diabetes clinics. [21] 
 
2.2.1.6  Reimbursement 
People with type I or type II diabetes are eligible for free medication 
from the Government Hospitals, ie. Insulin (human, all types with pen 
injector), tablets for monitoring diabetes and any other drugs for 
complications caused by diabetes, as well as strips for blood glucose 
analyses. [26] 
In March 2005 the Ministry of Health introduced a new policy 
designed to reduce the costs of pharmaceuticals in Cyprus. Patients suffering 
from diabetes should benefit by a reduction of up to 53% in the price of 
treatment. [29] 
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2.2.2 Incidence of type 1 diabetes  
 
 
2.2.2.1  Incidence of insulin dependent diabetes mellitus in Greek 
Cypriot children and adolescents, 1990-1994. 
 
 The objective of this study was to estimate the incidence of type 1 
diabetes mellitus (IDDM) in the Greek population of Cyprus based on 
epidemiological data collected during the period 1990-1994. 
 
Insulin dependent diabetes mellitus (IDDM) is one of the most 
common chronic diseases among children and adolescents worldwide. It has 
been well established that there are marked geographic differences in the 
incidence of IDDM, which may provide important clues concerning its as 
yet unknown etiology. The results of this survey showed that the incidence 
of IDDM in the Greek population of Cyprus is 10.5/100,000 population 
under the age of 15 years, which is in agreement with other European 
countries. There was a slight increase in the number of newly diagnosed 
patients in 1994. The mean age of onset is 8 years whereas the peak age of 
onset occurs at 11-12 years. There is a slight overall female predominance 
but not among children who manifest IDDM before the age of five years in 
whom males significantly predominate. Distribution by month of onset of 
IDDM revealed an increased number of cases during autumn and winter as 
expected. [12] 
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2.2.2.2  The incidence of type 1 diabetes mellitus in Greek-Cypriot 
children and adolescents in 1990-2000. 
 
The oblective of this study was to ascertain the exact incidence of type 
1 diabetes mellitus (DM1) in Greek-Cypriots under the age of 15 yr, to 
analyze possible gender differences in the age of onset and to observe any 
seasonal variation in the manifestation of the disease. All cases of newly 
diagnosed DM1 patients under the age of 15 yr from 1990 to 2000 were 
collected and relevant information was obtained. The data were statistically 
processed in relation to the population data provided by the Department of 
Statistics and Research of the Ministry of Finance.  
 
 
The mean annual incidence of DM1 in the Greek population of 
Cyprus under the age of 15 yr for the period 1990-2000 is 11.32/100,000. 
There is a trend towards increasing incidence during this period. There is a 
gender influence on the age of onset: more males develop DM1 before the 
age of 6 yr and after 13 yr. Moreover, there is a gender difference in the 
group who manifest DM1 in the age range 5-9 yr, with females having a 
mean age of onset of 8.1 yr, compared with 7.3 yr for males. There is a 
statistically significant seasonal variation, but not among preschool subjects 
who manifest DM1 before the age of 4 yr. DM1 is a common condition in 
Greek-Cypriots under the age of 15 yr. The gender difference in the age of 
onset probably reflects the peripubertal period of each gender. The seasonal 
variation cannot be solely attributed to weather and temperature changes. 
This survey covers a 10-yr period and deals with an adequate number of 
reported cases; therefore, it could contribute to the international effort to 
determine the exact pathogenesis of DM1. [11] 
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2.2.3  An Epidemiologic Study on the Prevalence of Diabetes, 
Glucose Intolerance, and Metabolic Syndrome in the Adult 
Population of the Republic of Cyprus  
 
The study was conducted in Cyprus (November 2003 through January
 
2005). Stratified random sampling was used to select 1,200 individuals
 
aged 
20–80 years (from a total population of 477,000). In all subjects, 
anthropometrical measurements were taken, fasting
 
lipids were measured, 
eating habits were evaluated according
 
to a standardized questionnaire, and 
an oral glucose tolerance
 
test (OGTT) was performed (except in known 
diabetic patients).
  
 
 
In the absence of OGTT-diagnosed diabetes or impaired glucose
 
tolerance (IGT), impaired fasting glucose (IFG) was defined
 
by fasting 
plasma glucose 110 mg/dl and <126 mg/dl, whereas
 
"new" IFG was defined 
by fasting plasma glucose 100 and <126
 
mg/dl. Metabolic syndrome was 
defined according to the National
 
Cholesterol Education Program Adult 
Treatment Panel III criteria.
  
[13] 
Of the 1,200 subjects, 78 (6.5%) had known diabetes and 45 (3.8%)
 
were newly diagnosed by the OGTT, which brought the total prevalence
 
of 
diabetes to 123 (10.3%). Another 78 (6.5%) subjects had IGT,
 
36 (3.0%) had 
IFG, and 171 (14.2%) had "new" IFG. Logistic regression
 
showed that 
significant risk factors for diabetes were age,
 
male sex, family history of 
diabetes (P < 0.001), hypertension
 
(P = 0.004), and obesity (P = 0.003). Risk 
factors for IGT were
 
age and family history of diabetes (P < 0.01). Risk 
factors
 
for IFG and "new" IFG were age and obesity (P < 0.01).
   
[13] 
The prevalence of metabolic syndrome was 22.2% overall, 68.5%
 
among subjects with diabetes, 43.6% among those with IGT, 86.1%
 
among 
subjects with IFG, 35.7% with "new" IFG, and 12.3% among
 
subjects with 
normal glucose tolerance. The prevalence of metabolic
 
syndrome increases 
with age, is higher in men than in women
 
(26.5 vs. 18.3%, respectively, P = 
0.001), and is higher in
 
rural than in urban areas (26.0 vs. 20.6%, 
respectively, P =
 
0.037). [14]
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The average daily energy intake was 2,509 kcal, to which 
carbohydrates
 
contributed 53.3%, fats contributed 31.8%, and proteins 
contributed
 
14.9%. Comparing the OGTT(–) group with the three groups of 
various degrees of glucose intolerance, after age and sex
 
adjustment, no 
differences were found regarding energy intake
 
(range 2,551–2,231 kcal) or 
the qualitative composition
 
of the diet (carbohydrates 53.1–54.9%, proteins 
14.4–15.4%, and fats 30.7–32.1%). Moreover, the above parameters did not 
differ between subjects with or without metabolic syndrome.
 
[14] 
 
In conclusion, the study revealed a very high prevalence of
 
diabetes 
and IGT in Cyprus, among the highest in Europe, compared
 
with five centers 
of the DECODE (Diabetes Epidemiology: Collaborative
 
Analysis of 
Diagnostic Criteria in Europe) study (1) and higher
 
than in the U.S. (2), 
while the prevalence of metabolic syndrome
 
is comparable with that of other 
Western countries (3). Dietary
 
habits, evaluated by cross-sectional analysis, 
do not seem to
 
contribute to the development of glucose intolerance. 
Interventions
 
aimed at IGT and the components of metabolic syndrome are 
urgently
 
needed in order to reduce the incidence of diabetes.
  
[13] 
 
 
 
 
 
2.2.4  Genetic predisposition to DM 1 in the Greek-Cypriot 
population 
  
 
Genetic linkage of diabetes mellitus type 1 (DM1) with certain HLA 
alleles is still of scientific interest. The aim of this study is to identify the 
association of HLA alleles with DM1 in Greek Cypriots. 
 
 
101 DM1 patients with age of onset less than 15 years were HLA 
typed using PCR/SSOP and PCR/SSP methods and compared to 209 
controls randomly selected from a population of healthy volunteer donors. 
Statistical analysis was performed using the SPSS statistical package. [15] 
The results are shown in the table below: 
HLA DM1 % CTL % Odds Ratio (95% CI) Fisher.s test 
DR4 66 18 8.735 (5.076-15.033) P<0.001 
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DR3 50 13 6.741 (3.839-11.837) P<0.001 
DR5 9 56 0.079 (0.38-0.166) P<0.001 
DR2 25 46 0.385 (0.227-0.653) P<0.001 
DR3 or 4 92 30 27.266 (12.486-59.542) P<0.001 
DQ2 73 27 7.230 (4.237-12.337) P<0.001 
DQ3 49 54 0.802 (0.499-1.289) P<0.214 
DQ2 or 3 95 73 7.278 (2.819-18.792) P<0.001 
High resolution testing of the DR4 and DR3 alleles revealed the 
predominant presence of the DRB1*0403 (0% vs 36%), similar frequency of 
the DRB1*0402 in both groups (19% vs 14%) and that DRB1*0301 was the 
only DR3 allele detected. The DQB1 alleles were nearly exclusively 
DQB1*0201 and DQB1*0302. [15] 
DM1 in our population seems to be linked to HLA: 
DRB1*0301 and DRB1*0405 which are associated with DQB1*0201 and 
DQB1*0302. A negative association and possible protection from DM1 of 
DR5 and DR2 antigens is also considered. Further studies on the HLA and 
other genes are needed to uncover the immunogenetic basis of DM1. [15] 
 
 
 
 
 
2.2.5 Prevalence of type 2 diabetes and physical activity status 
in elderly men and women from Cyprus (the MEDIS 
Study). 
 
 
The aim is to investigate the association of being physically active on 
the prevalence of Type 2 diabetes mellitus among elderly people.  
 
 
There was enrollment of 53 men and 97 women, aged 65 to 100, from 
various areas of Cyprus. Physical activity was evaluated through a validated 
questionnaire (the short International Physical Activity Questionnaire, 
IPAQ). Prevalence of diabetes was 26% in men and 18% in women, while 
55% of men and 50% of women were reported as being moderately or 
vigorously active. Furthermore, 5% of the participants reported that they 
smoked, 4% had stopped smoking, and 8% reported alcohol consumption. 
People in the upper tertile of the IPAQ score were 0.26 times less likely to 
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have diabetes (p < 0.05); on the other hand people in the lower tertile of the 
score were 1.7 times more likely to have diabetes (p < 0.05). [39] 
 
Findings support the notion of a beneficial effect of physical activity 
on the burden of diabetes in the elderly. [39] 
 
 
 
 
 
 
2.2.6  Case studies made in Cypriot patients 
 
 
 The aim of the following case studies was to show the connection of 
diabetes mellitus with different complications and the great importance of 
the preventable measures that must be taken to avoid these complications. 
These case studies were taken from the Makarios Hospital of Nicosia, in 
Cyprus. 
 
 
1. J.K., a 45-year-old female, was 1.59m and weighed 73kg. She had 
urinary tract infections once or twice each month within the last 12 months. 
Her other symptoms and signs included constant thirst, increased fluid 
intake, increased frequency and volume of urination. She was diagnosed 
with diabetes mellitus after testing positive for high levels of blood glucose. 
She was prescribed Equilibrium, 4 capsules TID before meals. Two weeks 
after the initial treatment, she reported significant improvement of her signs 
and symptoms. Two months after the initial treatment, her blood glucose 
levels were within the ideal range. She did not have any urinary tract 
infections during these two months. She continues to take Equilibrium, 4 
capsules TID before meals. [16] 
Clinical Note: Urinary tract infection is a common complication of 
chronic diabetes. The frequency of infections, polydipsia and polyuria, in 
combination with her age and body weight, indicated possible diabetes. Prior 
to treating the urinary tract infection, her blood glucose levels must first be 
tested to rule out diabetes. In this case, persistent high levels of blood 
glucose levels confirmed the diagnosis of diabetes mellitus. After treatment 
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with Equilibrium for two months, both symptoms and complications of 
diabetes mellitus were under good control. [16] 
 
2. A.G., a 60-year-old male, was 1.83m and weighed 127kg. He was 
always hungry and ate two or three bowls of rice with every meal. He 
noticed that his cuts or scratches required a longer period of time to heal, 
sometimes up to one month. His diagnoses were diabetes mellitus and high 
cholesterol. He was given Equilibrium, 4 capsules TID for his diabetes, and 
Cholisma, 4 capsules TID for his cholesterol. After taking the herbs for three 
months, his blood glucose levels were within the ideal range and his 
cholesterol level dropped from 260 to 220. His weight also dropped from 
280 to 255 pounds. He ate less and did not feel constantly hungry. He 
continues to take both Equilibrium and Cholisma. [17] 
Clinical Note: High cholesterol levels are a common complication of 
diabetes mellitus. If untreated, high cholesterol levels can lead to 
atherosclerosis, hypertension, coronary heart disease, angina, and 
myocardial infarction. Therefore, effective treatment must address both 
blood glucose levels and blood cholesterol levels. In combination with 
dietary changes, this patient showed excellent progress in reducing his blood 
glucose and cholesterol levels. [17] 
 
 
 
 
 
 
2.2.7  Insulin in Cyprus 
 
 
In Cyprus, it was reported that two of the main problems relating to 
insulin, are the gap between private and public health care and the lack of 
treatment guidelines.  People with diabetes go to the hospital for their 
prescriptions, while going to the Private Sector for their consultations.  In 
North Cyprus, insulin is free of charge but there is an issue regarding 
availability; not all insulins are available.  If other types of insulin are 
needed, a request must be submitted to a panel of doctors.  The decision 
often takes a long time. [18] 
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2.2.8  Cyprus Diabetic Association (CDA) 
 
2.2.8.1  What care to expect when your child has diabetes 
The main aim of treatment for diabetes is to relieve the unpleasant 
symptoms of high and low blood glucose by maintaining near-normal blood 
glucose levels. Good diabetes control is not always easy to achieve. Most 
young people- and their parents- have difficulties with this at one time or 
another. But, with the support of the “ Children‟s Specialist Diabetes Team”, 
the child will be able to lead an active, healthy life with normal growth and 
development. [21] 
Children with diabetes have special needs to do with the fact that they 
are children. This is why it is essential that the child is looked after by a 
Specialist Children‟s Diabetes Team, and is seen at a special clinic just for 
children with diabetes. This way, the family of the child can meet other 
parents and children who are in the same position as them- and meet all the 
members of the team at one visit. [21] 
The child and his/her family are important members of the team too- 
after all, the child and the family will be “living with diabetes” day to day. 
The family‟s and child‟s input and experience is just as important as their 
contact with the diabetes team. [21] 
The Specialist Children‟s Diabetes Team in Cyprus includes: 
1. Consultant paediatrician with a special interest in diabetes- he/she 
has overall responsibility for the child‟s diabetes care, hand in hand with 
the other members of the team. His/her experience in childhood 
conditions and special knowledge of diabetes mean that the children can 
have the best possible care and advice. 
2. Paediatric diabetes specialist nurse- he/she has special expertise in 
children and diabetes, and can give advice and support for managing 
diabetes in hospital, at home, and at school. 
3. Paediatric dietitian- food is an important part of a child‟s life, even 
more so when the child has diabetes. The paediatric dietitian can give 
advice and support on the subject of the family‟s food. This will help the 
child to have good diabetes control and healthy growth. 
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4. Children’s clinical psychologist- diabetes affects many aspects of life 
for the child and the family, and this can lead to emotional stress. The 
family should be able to contact a children‟s clinical psychologist with 
experience in diabetes if needed. 
5. Family GP- he/she will still look after the child for non-diabetes matters. 
There should be good communication between the child‟s GP and the 
diabetes team on the child‟s health. 
6. Senior paediatric ward nurse with experience in diabetes- hopefully, 
the child will not have much contact with the hospital ward after 
diagnosis, but the senior ward nurse can give advice if other members of 
the team are not available, or if the child does not need to go into hospital 
again. [21] 
 
Care at diagnosis (at hospital or at home) 
These days with newly diagnosed diabetes, children may receive their 
initial care and treatment either at hospital, at home or a combination of 
both, depending on the child‟s health and the facilities available in Cyprus 
health authority. [21] 
If the child is going to be cared for in hospital and is under 16, he/she 
should be admitted to a paediatric ward staffed by health care professionals 
experienced in childhood diabetes. There should be facilities for the parents 
to stay with their child at the hospital, and the amount of time the child 
spends away from home should be kept to a minimum. [21] 
In some cases, the child may be treated at home by a children‟s 
specialist paediatric diabetes team, if he/she does not have ketoacidosis, (a 
complication of diabetes that needs to be treated in hospital). The child may 
be able to spend the day at home and sleep at the hospital at night. [21] 
Such “home-based” diabetes services for children, though not 
widespread, are being developed in some areas of Cyprus especially in the 
capital city Nicosia. [21] 
Whether the child is to be at hospital or at home in the first few days 
after diagnosis, there are certain things that should happen: 
1. The family should be given an explanation of diabetes from a senior 
member of the medical team, and appropriately written information on 
diabetes to back this up. 
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2. The family should be given time to absorb the fact that the child has 
diabetes, and a chance to talk over the emotional impact of diabetes 
on the child and the rest of the family. 
3. The family should be able to talk over their concerns with senior staff 
while the child is in hospital or being looked after at home. 
4. One of the diabetes team should inform the family‟s GP about their 
child‟s diabetes, and offer to get in contact with the school. 
5. The family should have several sessions with a paediatric dietitian 
who can give them dietary advice and help them make any changes 
that are needed to the child‟s diet. 
6. The family should be seen by a paediatric diabetes specialist nurse. 
7. The family should be given information about the CDA ( Cyprus 
Diabetic Association), family support groups in their area, and how to 
claim Disability Living Allowance to help cover the home supervision 
of their child now that he/she has diabetes. [21] 
 
Continuous care 
At diagnosis and in the weeks and months following the child‟s 
diagnosis, members of the diabetes team will give the family and the child 
more detailed information on how to control and manage diabetes. This 
should include: 
1. Information and advice on how and where to inject, injecting devices, 
and how to dispose of needles and finger pricking lancets. 
2. How and when to test blood for glucose levels and urine for ketones, 
what the results of these tests mean, and when to seek advice. 
3. Information about how insulin, food, exercise, stress and excitement 
interact, and how they affect blood glucose levels. 
4. A discussion about hypoglycaemia ( hypos) with clear information 
about its causes, symptoms and treatment. This should include the use 
of Glucagon and/or Hypostop. The family should be given 
information on convulsions ( fits) which can occasionally be caused 
by hypos, and how to deal with them. 
5. An explanation of what is called the “honeymoon” phase- the time 
shortly after diagnosis when the child may need less insulin. 
6. An explanation that the child may find it hard to adjust to early day to 
day life with diabetes. 
7. The family should be given a telephone number to call for 24-hour 
advice from members of the diabetes team or the paediatric ward. [21] 
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Once the child’s diabetes is reasonably controlled 
After a time, the family will become more confident in managing their 
child‟s diabetes. However, the diabetes team should always be available 
when and if the family need them. They will maintain contact to continue 
their education programme and to support the family. The family should not 
hesitate to ask for more help or information. [21] 
Then the following could be expected: 
1. The family and their child should see a paediatric diabetes specialist 
nurse, consultant and dietitian frequently in the weeks and months 
after diagnosis. Once the family feels more confident in managing 
their child‟s diabetes, they will need to visit the clinic at least 3 or 4 
times a year as part of their child‟s regular diabetes care. 
2. At the visits, the child‟s general health will be checked and his/her 
blood glucose will be reviewed by looking at the family‟s home 
records, and by some extra tests of long term blood glucose control. 
3. The family, especially the parents, should have a chance to get further 
education about diabetes, and discuss any other concerns that the 
family may have about diet, insulin, hypoglycaemia or any other 
aspect of living with diabetes. 
4. As the child gets older there will be opportunities to discuss how 
he/she is coping with diabetes and life in general. There may be some 
emotional or behavioural problems that the family is finding difficult 
to manage on their own; perhaps the child is refusing to do blood 
tests, or worried about being bullied at school. If this is the case, the 
family should be able to get help from a psychologist or counsellor as 
part of the child‟s diabetes care. [21] 
 
 
2.2.8.2  Child’s annual review 
Children with diabetes should have a complete medical check by the 
diabetes team. This may take the form of a yearly review or it may take 
place at each visit. This will show how the child is managing with injections, 
diet and diabetes control. It also allows the team to check for any signs of 
diabetes “complications”, which can affect the feet, eyes and kidneys. [21] 
 88 
Complications are rare in children, and we know that good diabetes 
control greatly reduces the risk. However, it is sensible for the child to have 
regular checks ( at least once a year) so that any problems can be picked up 
and treated. [21] 
This review includes: 
1. Blood tests 
2. Urine tests 
3. A blood pressure check 
4. Check of injection sites 
5. A food examination 
6. A review of diet  
7. A check of weight and height 
8. An eye examination( from the age of 12 onwards) 
9. The diabetes team should note how many hypos, admissions to 
hospital and days missed from school due to diabetes the child has had 
in the past year. 
10. Discussion of any worries the family may have, and setting realistic 
targets for control and management for the coming year. [22] 
 
 
2.2.8.3  Emotional support 
Learning that your child has diabetes is a traumatic event for any 
family. Adapting to and managing diabetes upsets the normal routine at 
home and can place a strain on family relationships. Diabetes can be fitted 
into an active and healthy life, and settled home life, but the family needs 
help and support to do this. This is why diabetes care in Cyprus should also 
include input from a psychologist and/or counsellor if needed. Extra support 
may be needed, for example, to help the child make the change to an adult 
diabetes team. [22] 
 
Diabetes at school 
It is important that there is good communication between the child‟s 
school staff and the diabetes team. In most instances the diabetes nurse 
specialist will visit the school to talk to the child‟s teacher and other staff 
about diabetes. He/she can explain about hypoglycaemia, the child‟s meal 
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and snack times, exercise and who to contact in an emergency. The CDA ( 
Cyprus Diabetic Association) can supply a free School Pack for school 
staff. This is also useful for the paediatric diabetes specialist nurse, who can 
take it on school visits and leave it for the staff. [21] 
 
Changing to an adult clinic  
As the child gets older, the diabetes team will be trying to encourage 
him/her to take on more responsibility for doing their own injections and 
blood tests and keeping a record of their test results. In this way, the child 
will start to understand how food, exercise and insulin affects their diabetes, 
and how to make adjustments to “ keep in control”. [22] 
When the child reaches the mid teenage years ( generally 16 and over) 
he/she will probably come under the care of a new diabetes team, 
specialising in adults with diabetes. Exactly when this happens depends on 
the individual child and the facilities available in his/her area. [21] 
It can be a difficult time for the child, as he/she will have got used to 
the paediatric team and perhaps made friends with other children attending. 
[21] 
But the paediatric team and the adult team should work together to 
make sure the transfer is as smooth as possible. [22] 
 
2.2.8.4  How the CDA can help 
The Cyprus Diabetic Association is an excellent source of support and 
information for Cypriots living with diabetes, which includes the parents. 
Families with a child under 16 years old can join the CDA free for the first 
year. [21] 
1. Balance, the CDA‟s magazine for members, is full of interviews, 
features, research updates and recipes, showing the people that 
diabetes needn‟t hold them back from a healthy, active lifestyle. They 
can also receive Young Balance, a series of pages especially for 
children with diabetes. 
2. The CDA‟s Balance for Beginners range is designed to help people 
who are newly diagnosed with diabetes. The CDA has magazines for 
parents of children with diabetes, for children, teenagers, and for 
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adults with insulin dependent diabetes. The CDA also has a large 
selection of leaflets and books on all aspects of diabetes. 
3. The CDA can offer reassurance through their confidential information 
and support service, Careline. Through Careline, CDA can provide 
Cypriots with general information on diet, hypoglycaemia, injections 
and testing, disability living allowance, employment issues and much 
more – for individual medical advice, the patient‟s diabetes nurse 
specialist and diabetes team are best qualified to help. There are 
number of self help groups especially for parents of children with 
diabetes, within CDA‟s nationwide branch network. 
4. The Youth & Family Services department at the CDA runs a range of 
fun and educational holidays for children and teenagers, giving the 
child the chance to meet others the same age with diabetes and learn 
more about their condition. 
5. CDA‟s Family Weekends are open to the whole family. Children are 
entertained by experienced helpers while the family has a chance to 
meet paediatricians, nurses and dietitians in an informal setting. 
6. The CDA runs the Parent Network, which sends out a newsletter, Link 
Up, four times a year. There are special groups within this which 
discuss their own needs, including single parents, parents of children 
under five, parents of children with diabetes and another condition. 
[21] 
 
 
 
2.2.9  Diabetes control in Cyprus and other Mediterranean 
East countries 
 
 
The scale of the problem that diabetes poses to regional health is still 
widely under-recognized and presents a daunting public health challenge. 
Recent estimates predict that if current trends continue, the number of 
persons with diabetes will more than double, especially in the less developed 
countries of the Region. Recent studies from Bahrain, Oman and Saudi 
Arabia showed that diabetes prevalence ranges between 13% and 15%. The 
Regional Office supported efforts towards enhanced surveillance, 
epidemiology and prevention of diabetes mellitus, and financial support was 
offered for surveys and studies in Islamic Republic of Iran, Jordan, Lebanon, 
Oman and Saudi Arabia. Significant progress in early detection and 
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treatment of complications was made in Bahrain, Cyprus, Kuwait, Oman and 
Saudi Arabia, and in promoting healthy lifestyles, in a healthy nutritional 
strategies workshop held in Lebanon in June 2000. The majority of countries 
of the Region have established, published and distributed guidelines on 
diabetes education materials focusing on community-based aspects. Bahrain, 
Jordan, Oman and Saudi Arabia made progress in developing national 
diabetes programmes, with emphasis on primary health care implementation 
and community awareness. Workshops on diabetes control for physicians 
were conducted in Bahrain, Egypt, Jordan, Lebanon, Oman, Pakistan, Saudi 
Arabia, Sudan and Tunisia, for both ministry of health staff and the private 
sector. [18] 
More efforts are needed, especially to accord high priority to diabetes 
control, provide adequate budgetary resources and conduct national 
community-based surveys. [19] 
 
 The aim of the following table is to show the present prevalence of 
diabetes mellitus among East Mediterranean countries, and in what extend it 
will be in the future. The data were collected from the World Health 
Organization (WHO). 
 
Table3. Prevalence of diabetes in the WHO Eastern Mediterranean Region 
 
Country  2000  2030  
Afghanistan  468,000  1,403,000  
Bahrain  37,000  99,000  
Cyprus  50,000  87,000  
Djibouti  7,000  9,000  
Egypt  2,623,000  6,726,000  
Islamic Republic of Iran  2,103,000  6,421,000  
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Iraq  668,000  2,009,000  
Jordan  195,000  680,000  
Kuwait  104,000  319,000  
Lebanon  146,000  378,000  
Libyan Arab Jamahiriya  88,000  245,000  
Morocco  427,000  1,138,000  
Oman  113,000  343,000  
Pakistan  5,217,000  13,853,000  
Qatar  38,000  88,000  
Saudi Arabia  890,000  2,523,000  
Somalia  97,000  331,000  
Sudan  447,000  1,277,000  
Syrian Arab Republic  627,000  2,313,000  
Tunisia  166,000  388,000  
United Arab Emirates  350,000  684,000  
Yemen  327,000  1,286,000  
Total  15,188,000  42,600,000  
Resource: http://www.who.int/diabetes/facts/world_figures/en/index.html. 
 
 
 
 
The prevalence is estimated to be increased: 
 By 43% in Cyprus 
 By 63% in Bahrain 
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 By 61% in Egypt 
 By 67% in Iran 
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2.3  DIABETES MELLITUS IN THE EU 
 
 
 
 The aim of the following description is to show the general situation 
concerning diabetes mellitus in the EU, including the prevalence of diabetes 
mellitus among EU countries, the costs of this disease, the plans taken for 
the prevention and diabetes care, and the policy recommendations for 
diabetes prevention and control at EU and national levels. 
 
 
2.3.1  The size of the diabetes epidemic in the EU 
 
Diabetes mellitus is a mounting public health issue. Being a chronic 
and progressive process from hyperglycemia at its beginning to 
cardiovascular and so-called microangiopathic complications, the 
consequences of “the diabetes process” cannot be overestimated. The 
severity of the problem is largely accentuated by the growing prevalence of 
type II diabetes, and, to a lesser extend, type I diabetes. [26] 
Today, over 25 million people living with diabetes within the 27 EU 
member states are affected by the disease. The current EU average 
prevalence rate is estimated to be 7.5% of the total population aged 20 and 
above with all indications pointing to a continued increase in the coming 
years. [26] 
Prevalence rates in the new member states lie around 9% and beyond. 
[26] 
Based on population screening programmes, it is estimated that up to 
50% of all people with diabetes are undiagnosed: for every known diabetes 
case, an unknown one is detected. [26] 
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There is an alarming rise in the number of children diagnosed with 
type II diabetes. This audit revealed the incompleteness of existing data 
regarding this problem, and moreover, the lack of specific programmes to 
address it. [26] 
 
2.3.2  The personal and budgetary costs of the diabetes 
problem in the EU 
 
Diabetes mellitus is a major and growing epidemic with high cost and 
negative health implications, yet several EU governments lack a clear view 
of the disease‟s epidemiological burden, economic, personal, and societal 
impact. [27] 
The total cost of diabetes across the EU is estimated to account for 
2.5-15% of total healthcare spending (over half of member states have 
reported estimates of their spending on diabetes). [27] 
Evidence of the dramatic costs of treating diabetes and its 
complications are found in the CODE-2 study, which estimated the total 
direct costs of type II diabetes to be 29 billion Euros in 1998 for 10 million 
people with type II diabetes in eight EU countries ( Belgium, France, 
Germany, Italy, the Netherlands, Spain, Sweden and the UK). [27] 
Around 50% of the people with type II diabetes have already 
developed at least one complication by the time of diagnosis. Cardiovascular 
diseases leading to myocardial infarction and/or stroke, eye disease or 
retinopathy ( the leading cause of blindness), kidney failure, neuropathy and 
diabetic foot disease( predisposing to ulceration and limb amputation) are 
some of the most common complications of diabetes. [27] 
On average, those with type II diabetes will die 5-10 years before 
those without diabetes; most of this excess mortality is due to cardiovascular 
disease. About 80% of all people living with diabetes die of cardiovascular 
disease. [27] 
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Cardiovascular disease consumes by far the greatest proportion of 
direct costs and more than half of the mortality-related costs of diabetes. [27] 
The largest single item of diabetes expenditure is hospital admissions 
for the treatment of long-term complications such as heart disease, stroke, 
kidney failure and foot problems. Many of these complications are 
potentially preventable given prompt diagnosis of diabetes, effective patient 
and professional education and comprehensive long term care of people with 
diabetes. [27] 
The cost-effectiveness of diabetes management programmes depends 
on several factors such as diabetes epidemiology, healthcare organization 
and delivery of care. [27] 
With regard to general screening, questions remain over long-term 
benefits. Experts suggest that a more targeted approach towards high risk 
groups is probably the best and most profitable way forward. [27] 
 
2.3.3  Policies in place to address the diabetes problem in the 
EU 
 
11out of the 27 member states ( Austria, Czech Republic, Denmark, 
Finland, France, Germany, Italy, Portugal, Slovakia, the Netherlands and 
United Kingdom) are reported to provide a national framework or plan for 
diabetes prevention and care. Spain is unique as it has several regional 
diabetes plans but no national framework. [28] 
10 member states are addressing diabetes, either under the national 
obesity plan, or by developing national diabetes plans or screening 
programmes. Of these, seven member states are expected to have national 
diabetes plans in place by 2006 ( Austria, Ireland, Germany, Lithuania, 
Luxembourg, Spain and Poland). [28] 
Finland is a model for other member states because it has addressed 
the high prevalence of diabetes and associated healthcare costs. Germany 
and Slovenia have indicated their intention to model national programmes of 
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the Finnish example: however, outcome data from the Finnish programme 
are not available. [28] 
The Netherlands report one of the lowest prevalence rates (3.7%) and 
the lowest healthcare diabetes costs (2.5% of total healthcare budget) among 
all EU member states. Nevertheless, it has recently developed a national plan 
for improved diabetes care focusing on a multidisciplinary approach. [28] 
Most member states (19 out of 27) have nationwide clinical evidence-
based guidelines for type I and/or type II diabetes. [28] 
Prevention of obesity together with secondary prevention and 
intervention measures are key factors in delaying and reducing the risk of 
complications such as cardiovascular disease, blindness or amputations. [28] 
All 27 member states of the EU (with the exception of Cyprus) 
adopted the St Vincent Declaration in 1989. Even when member states have 
established national plans, these as such are not a measure of success unless 
they are being implemented; the level of resources and implementation of 
plans was reported to be unsatisfactory in many countries. [28] 
Progress made with strategies addressing cancer and cardiovascular 
disease, at both national and international levels, demonstrates the wisdom 
of addressing equally devastating conditions such as diabetes in a similarly 
co-ordinated, strategic and comprehensive way. [28] 
 
2.3.3.1 Identified gaps in diabetes policies 
 
The starting point for any comprehensive and credible policy is the 
availability of data on the extent and magnitude of the problem, i.e. an 
accurate diagnosis is the key. There is a lack of cost data in many countries, 
such as Cyprus, Estonia, Greece, Latvia, Luxembourg, Malta, Slovakia, 
Slovenia and Sweden. Governments, diabetes associations, health 
professionals and people living with diabetes need to be aware of the current 
and future economic impact of the disease. National diabetes registers 
(NDRs) of people with diagnosed diabetes are helpful so that effective 
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diabetes care can be delivered and outcomes monitored as outlined in the 
targets of the St Vincent Declaration. We found that very few countries have 
developed NDRs. Furthermore, according to experts the lack of electronic 
record linkage or sophisticated monitoring facilities should not prevent 
diabetologists and general practitioners continuing to refine their data 
collection on these patients. 13 Several member states have ad hoc screening 
programmes to reduce complications. However, only a few member states 
have set national screening targets, such as the UK, Finland and France. 
There is no collection of data on hard outcomes following the 
implementation of programmes; CVD and mortality rates are not measured, 
leading to inability to assess cost-effectiveness of programmes. The 
development of information technology is necessary if the scale of the 
epidemic and outcomes are to be properly recorded. [26] 
 
2.3.3.2 Policy recommendations for diabetes prevention and 
control 
 
POLICY RECOMMENDATIONS AT EU LEVEL 
 
 
Article 152 of the EU Treaty of Nice provides that EU action is to 
complement national policies and be directed towards improving public 
health, preventing human illness and diseases and obviating sources of 
danger to human health. Such action shall support the fight against the major 
health scourges by promoting research into their causes and their prevention 
as well as health information and education. EU action in public health shall 
respect fully the responsibilities of member states for the delivery of health 
services and medical care. In this context, the proposed EU Programme of 
action in the field of health and consumer protection 2007 – 2013 seeks to 
improve the health of citizens throughout their lives, improve health as a 
human right and encourage investment in health, including the promotion of 
policies that lead to a healthier way of life and help to reduce the incidence 
of major diseases. However, as it stands this programme fails to address 
diabetes specifically as a disease that requires attention and community 
action. There is a definite need to identify diabetes as a priority disease at 
EU and national level and to encourage the exchange of best practice to 
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optimise resources while raising the standards across Europe as regards 
prevention, screening and treatment. Currently there is no forum of 
exchange of such practices within the EU other than ad hoc forums created 
by Council Presidencies. It is urged the European Commission and European 
Parliament to examine the current epidemiological evidence and the policy 
gaps across Europe with regard to diabetes. The European Commission 
should address the European epidemic by developing a coordinated and 
comprehensive EU strategy for diabetes which could make a significant 
contribution to the reduction of public health expenditures in all 27 EU 
member states. Based on the precedent of EU action in the field of cancer 
and the EU Council Recommendation on Cancer Screening, it is specifically 
encouraged the EU Commission to present an EU Council Recommendation 
on diabetes prevention and screening for adoption by member states. 
Although nonbinding for member states, such a Recommendation would 
provide an EU legal framework for action to improve the collection of data, 
to take appropriate primary prevention measures, to encourage the 
development of screening programmes and finally to monitor and evaluate 
outcomes – while respecting member states‟ responsibility for the delivery 
of health services and medical care. [27] 
 
 
POLICY RECOMMENDATIONS AT NATIONAL LEVEL 
 
 
It is crucial that member states improve the collection of 
epidemiological data on a regular basis. The EU should provide common 
criteria for the collection of such data so as to be able to compile and report 
comparative data at EU level. National registers of diabetes patients are a 
useful tool both from an individual perspective – they enable all those with 
diabetes to be identified – as well as from a public health perspective. All 
member states should gather comprehensive economic data about the costs 
of diabetes prevention and treatment. This is essential if policy decisions are 
to be taken to optimise limited resources. Such data are also needed to 
evaluate the effectiveness of different approaches to prevention and disease 
management. Member states should each have a national plan for diabetes 
prevention and care with measurable targets and an evaluation system to 
track health outcomes and cost-effectiveness of measures. Specific primary 
prevention programmes covering the whole population should be developed 
to promote a healthy lifestyle. Specific policies for school children should be 
developed, and particularly for children at increased risk of developing 
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obesity and diabetes (genetic and/or socio-economic factors, overweight, 
poor diet and lack of exercise). The development of primary screening and 
diagnosis programmes should be encouraged. Member states need to define 
targeted populations – based on local epidemiology and available resources 
– and screening policies to identify individuals at risk of developing diabetes 
and those with undiagnosed diabetes who risk developing costly 
complications. The implementation of secondary screening and prevention 
of complications in patients with diagnosed diabetes should be encouraged. 
Nationally-agreed guidelines with targets for disease management should be 
established and measured for health outcomes. A holistic approach to 
management of the disease is required where healthcare professionals work 
with patients and across sectors, i.e. Primary care, Community care, 
Secondary care, Social Services and Education institutes. Diabetes care 
requires an integrated approach. Investment in specific education and 
training of healthcare professionals in this disease area (physicians, diabetes 
specialist nurses, specialist dieticians, and other specialists) is essential to 
ensure that they can deliver high quality prevention, screening and care. 
Additional education and training at regular intervals should be made 
available to nonspecialist healthcare professionals to maintain safe practice. 
All people with diabetes should have an agreed individualised care plan 
which includes education, self management plan, review schedule and a 
named healthcare specialist. Member states need to make the political 
commitment to invest in the systems of care and infrastructure to ensure 
adequate implementation of national frameworks and to provide quality of 
care. Information technology is also needed to ensure good implementation 
and measurement of outcome data. Healthcare systems could save lives as 
well as billions of Euros annually with widespread use of healthcare 
information technology. [29] 
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The main goal of the following table is to show the prevalence of 
diabetes mellitus nowadays among European countries and the extent that 
the disease will take in the future years. It is seen that in some countries the 
prevalence will be doubled in some years and in some countries it will be 
even 3 times more than the present situation. The data were taken from the 
World Health Organization (WHO). 
 
 
Table 4.  Prevalence of diabetes in the WHO European Region 
 
Country  2000  2030  
Albania  86,000  188,000  
Andora  6,000  18,000  
Armenia  120,000  206,000  
Austria  239,000  366,000  
Azerbaijan  337,000  733,000  
Belarus  735,000  922,000  
Belgium  317,000  461,000  
Bosnia and Herzegovina  111,000  180,000  
Bulgaria  472,000  458,000  
Croatia  155,000  180,000  
Czech Rep.  336,000  441,000  
Denmark  157,000  232,000  
Estonia  46,000  43,000  
Finland  157,000  239,000  
France  1,710,000  2,645,000  
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Georgia  200,000  223,000  
Germany  2,627,000  3,771,000  
Greece  853,000  1,077,000  
Hungary  333,000  376,000  
Iceland  6,000  12,000  
Ireland  86,000  157,000  
Israel  257,000  500,000  
Italy  4,252,000  5,374,000  
Kazakstan  452,000  668,000  
Kyrgyzstan  98,000  222,000  
Latvia  82,000  90,000  
Lithuania  114,000  146,000  
Luxembourg  12,000  21,000  
Malta  39,000  57,000  
Monaco  2,000  3,000  
Netherlands  426,000  720,000  
Norway  130,000  207,000  
Poland  1,134,000  1,541,000  
Portugal  662,000  882,000  
Republic of Moldova  171,000  243,000  
Romania  1,092,000  1,395,000  
Russian Federation  4,576,000  5,320,000  
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San Marino  2,000  3,000  
Slovakia  153,000  220,000  
Slovenia  66,000  87,000  
Spain  2,717,000  3,752,000  
Sweden  292,000  404,000  
Switzerland  219,000  336,000  
Tajikistan  93,000  246,000  
The Former Yugoslav Republic of Macedonia  54,000  96,000  
Turkey  2,920,000  6,422,000  
Turkmenistan  80,000  222,000  
Ukraine  1,629,000  1,642,000  
United Kingdom of Great Britain and Northern 
Ireland  
1,765,000  2,668,000  
Uzbekistan  430,000  1,165,000  
Yugoslavia  324,000  393,000  
Total  33,332,000  47,973,000  
 
Resource:  http://www.who.int/diabetes/facts/world_figures/en/index.html. 
 
 
The prevalence is estimated to be increased: 
 By 30% in Germany 
 By 34% in UK 
 By 36% in France 
 By 41% in Netherlands 
 By 28% in Spain 
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2.4  Diabetes mellitus in Cyprus in comparison with EU 
 
 
 
 
 As it is seen there are a lot of differences between Cyprus and the EU 
as it concerns diabetes mellitus. Prevalence of diabetes is slightly higher in 
Cyprus than in the EU. The extend that the disease will take up to 2030 is 
similar for Cyprus and some member states, and for other member states the 
prevalence will be increased but not at the same extend but lower. As it 
concerns cost of diabetes from the total health care spending, EU has 
approximately 15% while in Cyprus it is not estimated precisely. The 
prevalence of undiagnosed patients with diabetes is slightly higher in the 
EU, and the same exists for the mortality and the risk for developing 
complications due to diabetes. EU has advantage over Cyprus in the 
guidelines and actions taken for prevention of diabetes and diabetes care, eg 
Czech Republic. All EU member states adopted the St. Vincent Declaration 
in 1989, with the exception of Cyprus. EU has also developed better 
strategies for preventing complications caused by diabetes. Cyprus has lack 
of cost data but this is not seen in most of the EU member states. Few 
member states have developed National Diabetes programmes, with Cyprus 
being in the process of doing it. [33] 
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2.5  Diabetes mellitus in Czech Republic 
 
2.5.1 General facts 
 
The objective of the following table is to show the total prevalence of 
diabetes among citizens of Czech Republic in 2003, the costs of this disease, 
and the actions taken from the state against the disease. The data were 
collected from the European Association for Study of Diabetes (EASD). 
 
Table 5.   Prevalence, cost and national plans for diabetes in Czech Republic 
FACTS  
Estimated prevalence (% of total 
population above 20 years old) 
9.5% 
Total diabetes prevalent cases 534,000-687,000 
Cost of diabetes (% of total 
healthcare budget) 
15% 
POLICY FRAMEWORK  
National Plan 1996 National Diabetes Programme 
Guidelines (Czech Diabetes Society) Standards 
of Care 
Planned Actions NDP evaluated in 2006 
Epidemiological 
survey/Assessment of Guidelines – 
expected in 2007 
Resource: European Association for the Study of Diabetes. www.easd.org. 
 
 
 106 
2.5.1.1  Incidence/Prevalence of diabetes 
The prevalence rate is estimated to be 9.5% according to the IDF 
Atlas. Over the last 30 years the number of people living with diabetes has 
more than doubled. [26] 
In 1975 there were 234,000 people living with diabetes, rising to 
687,137 in 2003. In 2003 type II diabetes represented 91.6% of cases. There 
is a growing incidence rate in both type II and type I diabetes, notably 
among children. Between 2000 and 2003, the number of people with 
diabetes increased by 5%. If this trend continues, by 2010 there will be an 
estimated 800,000 people living with diabetes, with a considerable number 
of undiagnosed, and an estimated 1,100,000 by 2020 (or a prevalence of 
11%). [33] 
Of major concern is that each year there is a growing number of 
patients with complications (173,000 in 2002 and 178,000 in 2003). The 
most frequent complications are retinopathy, nephropathy and insufficient 
blood supply in the legs. Women constitute a consistently higher proportion 
of people living with diabetes (by about 10%). [33] 
 
 
2.5.1.2 Cost of diabetes care 
According to the Czech Diabetes Society there are no accurate data, 
but estimates show that total expenditure on diabetes accounts for about 15% 
of the total budget for healthcare. [28] 
 
2.5.1.3 Government priorities 
Diabetes is seen as a government priority in addition to oncology and 
cardiology and the cooperation with the states‟ administration in this field is 
satisfactory. However, there remains room for improvement in prevention 
and early detection. [27] 
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2.5.1.4   Policy framework 
The Ministry of Health approved the 2
nd
 National Diabetes 
Programme (NDP) prepared by the Czech Diabetes Society (representing 
doctors) in 1996. The 1
st
 NDP dated from the 1980s. [26] 
The NDP was based on the St. Vincent Declaration and covers 
treatment and prevention, education of healthcare workers, social and legal 
aspects and science and research. The NDP is implemented in cooperation 
with the Ministry of Health, the Czech Diabetes Society, patients 
associations, the Coordination Group of the St. Vincent Declaration, the 
Ministry of Social Affairs and scientific and research centres. The 
Programme is due to be assessed in 2006. [29] 
Through a well-functioning monitoring system, the Czech Republic 
has a relatively good picture of the evolution of diabetes. [26] 
 
2.5.1.5 Guidelines 
The NDP is complemented by a comprehensive set of standards 
prepared by the Czech Diabetes Society. These guidelines, published in 
2004 in the Czech Journal “Diabetes, Metabolism, Endocrinology, 
Nutrition”, cover, inter alia, standards for diagnosis and care of type I and 
type II diabetes during pregnancy, self-control levels for blood sugar, care of 
diabetic nephropathy, care of patients with diabetic foot, treatment of 
diabetic retinopathy and its complications, and nutrition recommendations 
for people with diabetes. The guidelines are implemented nationwide and are 
subject to an update every two years. [27] 
The Czech Diabetes Society is currently undertaking a study of the 
“Evaluation of Diabetes Care in the Czech Republic” to measure the 
effectiveness of the guidelines. This epidemiological survey will cover a 
sample of 3,600 patients and will be repeated in 2006. Full results of the 
study are expected in 2007. [27] 
 
 
2.5.1.6  Reimbursement 
Health insurance provides nearly 100% reimbursement for diabetes 
care (insulin is covered by 90-100%; basic oral agents by 100%, and 400 
glucose strips by 100%). Since 1
st
 July 2005 the number of strips has been 
 108 
increased as a consequence of negotiations between the Czech Diabetes 
Society and the Ministry of Health. [29] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 109 
2.6  Diabetes mellitus in Cyprus in comparison with 
Czech Republic 
 
 
 There are some similarities and some differences concerning diabetes 
mellitus between Cyprus and Czech Republic. From the above mentioned 
for both EU member states it is seen that the prevalence of diabetes in 
Cyprus is slightly higher than in Czech. The same is for the extent that the 
prevalence of diabetes will take in the future years. Concerning the cost of 
diabetes, it is estimated that in Czech is approximately 15%  of the total 
health care budget (same as in EU), while in Cyprus the total cost is not 
estimated precisely but it is estimated that each person with diabetes is 
paying annually around 5000 Euros for therapy. Czech Republic has the 
advantage over Cyprus in the guidelines given, in that Czech Diabetes 
Society has evaluated diabetes Care with the Standards of Care, while 
Cyprus is still in progress for newly created diabetes clinics. Czech has 
developed a national plan which is the 1996 National Diabetes Programme 
(NDP), while Cyprus is in the process of developing a national plan. Planned 
actions in Czech Republic is the evaluation of the NDP in 2006, and also an 
Epidemiological Survey, with the assessment of guidelines expected in 
2007. [26] 
 Reimbursement for diabetes mellitus is one of the most important 
features in the treatment of diabetics in Cyprus and Czech Republic. In the 
case of Cyprus, there is reimbursement of insulin (all types with the pen 
injector), also for tablets for monitoring of diabetes, and other drugs for 
complications caused by diabetes, and strips for blood glucose analyses. All 
of them are provided by government hospitals with 53% benefit in the price 
of them. Unlike Cyprus, reimbursement for diabetes in Czech Republic is 
almost 100%. Insulin is covered by 90-100%, basic oral agents by 100%, 
and more than 400 glucose strips by 100%. [29] 
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2.7  Global Diabetes Problem 
 
 
2.7.1  Global prevalence of diabetes 
 
The goal of this study was to estimate the prevalence of diabetes and 
the number of people of all ages with diabetes for years 2000 and 2030. Data 
on diabetes prevalence by age and sex from a limited number of countries 
were extrapolated to all 191 World Health Organization member states and 
applied to United Nations‟ population estimates for 2000 and 2030. Urban 
and rural populations were considered separately for developing countries. 
 
 
The prevalence of diabetes for all age-groups worldwide was 
estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people 
with diabetes is projected to rise from 171 million in 2000 to 366 million in 
2030. The prevalence of diabetes is higher in men than women, but there are 
more women with diabetes than men. The urban population in developing 
countries is projected to double between 2000 and 2030. The most important 
demographic change to diabetes prevalence across the world appears to be 
the increase in the proportion of people 65 years of age. [32] 
 
 
These findings indicate that the “diabetes epidemic” will continue 
even if levels of obesity remain constant. Given the increasing prevalence of 
obesity, it is likely that the following figures provide an underestimate of 
future diabetes prevalence. [32] 
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Figure 1.  Global diabetes prevalence by age and sex for 2000. 
 
 
 
 
Resource: King H, Aubert RE, Herman WH: Global burden of diabetes, 
1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 
21:1414-1431, 1998. 
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Figure 2.   Number of people with diabetes by age in 2000 and 2030 in 
developed countries. 
 
Resource: King H, Aubert RE, Herman WH: Global burden of diabetes, 
1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 
21:1414-1431, 1998. 
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Figure 3.   Number of people with diabetes by age in 2000 and 2030 in 
developing countries. 
 
Resource: King H, Aubert RE, Herman WH: Global burden of diabetes, 
1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 
21:1414-1431, 1998. 
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Figure 4.   Number of people with diabetes by age in 2000 and 2030 in the 
world. 
 
Resource: King H, Aubert RE, Herman WH: Global burden of diabetes, 
1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 
21:1414-1431, 1998. 
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The aim of the following table is to show the total number of diabetics 
nowadays in the world and how it will be in the future years. The data were 
taken from the International Diabetes Federation (IDF). 
 
 
Table 6.   Prevalence of diabetes worldwide 
 
2000  2030  
World  171,000,000  366,000,000 
Resource: Diabetes Atlas, 3
rd
 Edition, International Diabetes Federation, 
2006. 
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2.7.2  Diabetes mellitus in USA 
 
The data were collected from the National Health and Nutrition 
Survey. The aim of the following figure is to show that prevalence of 
diabetes is increasing with age. 
 
Figure 5.   Prevalence of diabetes in 2005 in USA according age. 
 
Resource: U.S. Census Bureau, resident population estimates for 03/01/05. 
www.census.gov/popest/national/asrh/2004_nat_res.html. 
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The data were collected from the National Health and Nutrition 
Examination  Survey (NHANES), and the aim is to show what is the 
prevalence of diabetes among people of different ethnicities that live in 
USA.  
 
Figure 6.   Prevalence of diabetes in 2005 in USA according ethnicity. 
 
Resource: National Centre for Health Statistics, Centres for Disease Control 
and Prevention. 1999-2002, National Health and Nutrition Examination 
Survey (NHANES). www.cdc.gov/nchs/nhanes.htm. 
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The data were collected from the National Health Interview Survey. 
The aim of the following figure is to show the number of newly diagnosed 
diabetes among  people living in USA according age group. 
 
Figure 7.   New cases of diagnosed diabetes in USA 
 
 
Resource: National Centre for Health Statistics, Centres for Disease Control 
and Prevention. 1999-2003, National Health Interview Survey (NHIS). 
www.cdc.gov/nchs/nhis.htm. 
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 The data were taken from the National Health Interview Survey. The 
aim of the following figure is to show what pharmacotherapy are adults with 
diagnosed diabetes in USA take. The figure shows that more than 50% are 
treated only with oral hypoglycemics and 15% follow other therapy than 
with insulin or oral hypoglycemics. 
 
Figure 8.    Treatment of adults with diagnosed diabetes in USA 
 
Resource: National Centre for Health Statistics, Centres for Disease Control 
and Prevention. 1999-2003, National Health Interview Survey (NHIS). 
www.cdc.gov/nchs/nhis.htm. 
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2.8  Diabetes mellitus in the world in comparison with 
Cyprus 
 
 
 
 
If comparison is made between the global diabetes problem and the 
problem of diabetes in Cyprus, some similarities and some differences can 
be found. The prevalence of diabetes for all age-groups worldwide was 
estimated to be 2,8% in comparison with Cyprus which is higher (5-10%). 
By 2030 it is estimated that approximately 4,4% in the world will suffer with 
diabetes, while in Cyprus it will be more than 2 times the recent prevalence. 
Some similarities can also be observed. Both in Cyprus and the world there 
are more women with diabetes mellitus than men. In both cases there is 
increasing of the prevalence of diabetes with increasing age, especially in 
population above 65 years of age. [33] 
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2.9  Diabetes in the year 2010 – what will the future   
bring? 
 
 The main goal of the following article is to evaluate the significance 
of the prevention against diabetes mellitus and its complications, and if not 
taken, how the incidence of the disease will be increased in the next years. 
Also is to give some strategies concerning the pharmacotherapy of diabetes 
mellitus in the future. 
 
Although there are no definitive preventative measures that can be 
taken against diabetes at this time, except for identifying persons at high risk 
and encouraging appropriate dietary and exercise guidelines, research into 
the causes and control of this disease continues to provide the possibility of 
new cures. With the discovery of insulin in the 1920‟s and the development 
of oral hypoglycaemic drugs in the 1950‟s, a person who has diabetes can 
live an active and productive life. The importance of early detection and 
proper management of this chronic disease cannot, however, be emphasised 
too strongly. [38] 
The therapy of insulin-dependent diabetes will surely be altered 
dramatically over the next few decades. One can project that there will be 
improved strategies for glucose control in established IDDM. This will 
include the widespread use of mechanical devices, which will involve both 
implantable glucose sensors and implantable insulin infusion systems; and 
successful pancreas, islet or beta cell transplantation, in the absence of the 
need of immunosuppressive therapy to prevent rejection. [33] 
An inhaled form of insulin, under development for several years, 
appears to be ready for wide scale application by the year 2000. Recent 
studies conducted at the Universities of Miami and Vermont involving Type 
I and Type II patients demonstrated that inhaled insulin is at least as 
effective as injected insulin in controlling the symptoms of diabetes and has 
no side effects. The delivery system, whereby a finely powdered form of 
insulin is inhaled directly into the lungs, promises to greatly simplify 
management of both forms of diabetes. Powdered insulin requires no 
refrigeration and since it is absorbed into the bloodstream though the lungs, 
there will generally be no need for hypodermic needles. Type I patients will 
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still require an injection of slow-acting insulin at bedtime12. In the future it 
may also be possible to administer insulin in the form of a pill or patch. All 
of these advances will change the face of diabetes, as we know it. [9] 
Moreover, it will be seen the application of immune intervention 
strategies at the time of onset of IDDM, with the reversal of the disease 
process. Ultimately, these strategies will be applied earlier in the sequence 
during a stage that we do not yet recognise as clinical diabetes. In these 
individuals otherwise destined to develop IDDM, the disease will be 
prevented. [30], [33] 
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III. DISCUSSION 
 
 
 
 
The prevalence and the risk for complications of diabetes mellitus 
have been increased by the years and it‟s expected to be increased more in 
the future years, unless actions against its prevention are to be taken. 
NICE guidelines and recommendations against diabetes mellitus are 
from the best available nowadays, and they are one important measure 
against prevention of the disease, and if the disease exists, against prevention 
of complications associated with diabetes mellitus. In this thesis are 
described the guidelines that NICE provides for: 
 
 Management of type 1 and type 2 diabetes mellitus after diagnosis, 
including education, monitoring glycaemic control, management of 
diabetic ketoacidosis, screening for complications and associated 
conditions, arterial risk-factor control and psychological support. 
 Non-pharmacological treatment of both types with diet and exercise. 
 Pharmacological treatment of both types, including the insulin 
preparations (short-acting, intermediate-acting, long-acting insulin 
analogues), the insulin regimens, the types of insulin administration, the 
oral hypoglycemic drugs (metformin, sulphonylureas, acarbose), the 
newer agents in the market (thiazolidinediones, exenatide, liraglutide, 
sitagliptin, vidagliptin), and the combinations of these agents. 
 
Following these guidelines can help diabetic patients to control the 
status of the disease and increase their quality of life. 
 
The problem of diabetes mellitus has been described as the global 
problem, and more impact was given in the situation of the disease in 
Cyprus and EU. Some similarities and some differences were observed in 
the comparisons made between diabetes in Cyprus and EU, diabetes in 
Cyprus and Czech Republic, and finally diabetes in Cyprus against the 
global diabetes problem. These had to do with: 
 
 The Incidence/Prevalence of the disease. 
 The cost of diabetes care. 
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 The government priorities. 
 The Policy framework. 
 The guidelines given for prevention and control of diabetes. 
 The reimbursment of insulin and oral hypoglycemic agents. 
 
The prevalence of Diabetes mellitus in Cyprus in 2003 according IDF 
Atlas for population above 20 years old was estimated to be 5.1%  and today 
has reached 10.3%. It represents approximately the 2.1% of the disease 
burden in Cyprus and 2.3% of total deaths. Cardiovascular disease which is 
one of the many serious complications associated with diabetes, represents 
17% of the disease burden in Cyprus and is estimated to account for around 
41% of deaths in the country.  
The incidence for children below 20 years old with type 1 diabetes 
mellitus in 1990-1994 according a study was estimated to be 10.5/100000 
and until 2000 was increased to 11.32/100000. 
Cost of diabetes care in Cyprus has reached 5.8% of GDP in 2002 
against 2.8% in 1980. The growth rate for the last 5 years is estimated at 
2.3%. 
 
The prevalence of Diabetes mellitus in Czech Republic according IDF 
Atlas in 2003 for population above 20 years old was estimated to be 9.5%. 
In 2003, type 2 diabetes represented 91.6% of all cases. By the year 2020 
prevalence is estimated to increase by 11%. The most frequent 
complications seen in Czech diabetic patients are retinopathy, nephropathy, 
and insufficient blood supply in the legs. Women constitute a consistently 
higher proportion of people living with diabetes by about 10%. 
 
The current average prevalence rate of Diabetes mellitus in EU is 
estimated to be 7.5% of the total population aged 20 years old and above. 
Prevalence rates in the new member states lie around 9% and beyond. It is 
also estimated that 50% of all people with diabetes are undiagnosed. Very 
important point is that there is an alarming rise in the number of children 
diagnosed with type 2 diabetes. About 80% of all people living with diabetes 
die of cardiovascular disease. 
According WHO the incidence of diabetes mellitus by the year 2030 
will be increased in most of the countries, eg by 43% in Cyprus, by 30% in 
Germany, by 34% in UK, by 36% in France, by 41% in Netherlands, by 
28% in Spain. 
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The prevalence of diabetes for all age-groups worldwide was 
estimated to be 2.8% in 2000 and 4.4% in 2030. There are more women with 
diabetes than men. 
 
It is clear from the results that actions have to be taken immediately 
for prevention of the disease because diabetes is estimated to be increased by 
2 times and in some countries by 3 times, in the next 20 years. 
 
In most of the EU member states, the cost for diabetes care is almost 
15% of the total health care budget. This indicates the severity of the 
disease, and how important is the reimbursement of the specific 
pharmacotherapy. 
 
What is very interesting is that in Czech Republic and many EU 
member states, the reimbursement for management and pharmacotherapy of 
diabetes mellitus, including insulin, pen injectors, strips for blood glucose 
monitoring, and oral antidiabetic agents, is almost 100%. In Cyprus exists 
the reimbursement of all these but in a less extent (53%). In Cyprus the 
diabetic patients have to pay some amount of money for their 
pharmacotherapy. 
 
Another interesting point is that Czech Republic and some EU 
member states have developed national plans against diabetes mellitus, 
while Cyprus and most of the EU countries are still in the process of 
developing national plans against the disease. 
 
Case studies made in Cypriot diabetic patients were described to show 
the connection of diabetes mellitus with different complications and what 
measures must be taken to prevent these complications. 
 
One very interesting point is the diabetic care that Cyprus Diabetic 
Association (CDA) provides to the Cypriot diabetic patients and especially 
to the children with diabetes. It includes: 
 
 Care of children with diabetes at hospital and at home. 
 Regular annual checks for children with diabetes. 
 Emotional support. 
 Help through publication of various journals and with support services. 
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CONCLUSION 
 
 
 
 
 The main goal of this diploma thesis was to give the most effective 
guidelines and recommendations concerning non-pharmacological and 
pharmacological treatment for both types of diabetes mellitus, and to show 
the differences  and the similarities about situation of diabetes in Cyprus, the 
EU and generally the world. Among this goal was to show the severity that 
mainly type 2 diabetes mellitus has taken the recent years with the 
development of this disease not only in adults but also in children. 
 Diabetes mellitus as the disease was described according its definition, 
classification, clinical manifestations, complications diagnosis, non-
pharmacological and pharmacological treatment. 
 Evidence-based guidelines and recommendations were provided from 
NICE for the management, non-pharmacological and pharmacological 
treatment of type 1 and type 2 diabetes in children and adults. 
 More impact was given for type 2 than type 1 diabetes mellitus and 
type 2 diabetes in children was also described. 
 The general situation of diabetes mellitus, including its prevalence and 
incidence, cost of diabetes care, government priorities, policy framework, 
guidelines and reimbursement, was described for Cyprus, for EU, for Czech 
Republic and also for the world. Comparisons were made between Cyprus 
and EU, Cyprus and Czech Republic and finally Cyprus and the rest of the 
world. 
The results show that diabetes has become a leading cause of death in 
Europe and an increasingly uncontrolled health problem. It carries with it the 
risk of major cardiovascular complications and is now the commonest cause 
of hearth attack and stroke, a major cause of peripheral vascular disease and 
peripheral neuropathy leading to amputation and cause of micro vascular 
disease in the kidney and the eye. Diabetes is also the commonest cause of 
renal failure and blindness in Europe. 
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The European Union has leading role to play in shaping policy and 
action to encourage member states to provide adequate prevention, diagnosis 
and control of diabetes. Despite today‟s unhealthy lifestyles and poor 
nutritional habits, few appropriate public health measures are currently being 
taken to address the increasing prevalence and cost burden of diabetes. 
  
The Cyprus Diabetic Association (CDA), in cooperation with the 
Ministry of Health should focus not only in the pharmacotherapy of diabetes 
mellitus but it is of great importance, among their national plans to focus on 
the prevention of the disease and to find ways to inform not only the patients 
but generally the population about the severity of the disease and the ways to 
prevent it. 
 One very important measure is that national plans against the disease 
should be developed as soon as possible from the government of Cyprus and 
more diabetic clinics should be built so that the disease would be better 
tollerated and diabetic patients should have the best possible care to be able 
to control their disease. 
While many current and future European Union Member States, eg. 
Czech,  have established national diabetes plans, the European Union still 
lacks an overall public health framework that calls for the sharing of best 
practices and benchmarking of national approaches to the direct benefit of 
the individual patient. Such a framework could also encourage the creation 
of minimum standards for diabetes prevention, diagnosis and control, 
including early screening and appropriate intervention on glycaemic control, 
hypertension and dyslipidaemia. 
 
New data from the International Diabetes Federation show that more 
than 230 million people, almost 6% of the world‟s adult population, now 
live with diabetes. Previous figures underestimated the diabetes threat and 
the total is expected to rise. 
The number of people living with diabetes is expected to grow to 350 
million in less than 20 years if action is not taken. Diabetes is increasing 
faster in the world‟s developing economies than in developed countries.  
Seven out of ten countries with the highest number of people living with 
diabetes are in the developing world. IDF predicts that by 2025 almost 80% 
of all diabetes cases will be in low- and middle-income countries. If nothing 
is done, diabetes will place severe economic, social and health burdens on 
the countries that can least afford it. The disease threatens to subvert the 
gains of economic advancement.  
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Diabetes is emerging fast as one of the biggest health catastrophes the 
world has ever seen. The diabetes epidemic will overwhelm healthcare 
resources everywhere if governments do not wake up and take action now. 
Despite its alarming human toll, claiming as many lives as HIV/AIDS, 
there is an extraordinary lack of awareness of the global scale of the diabetes 
threat. The „Unite for Diabetes‟ campaign aims to gain support from 
governments for a United Nations Resolution on diabetes in order to raise 
awareness of the disease and improve diabetes care globally. 
Diabetes is one of the major causes of premature death worldwide. 
Every 10 seconds a person dies from diabetes-related causes. The death rates 
are predicted to rise by 25% over the next decade. According to the World 
Health Organization, the disease could reduce life expectancy globally for 
the first time in 200 years. 
Despite these alarming figures, little political effort has been made. 
The international community needs to start taking the threat seriously. 
Diabetes can be effectively managed, its impact reduced and its onset in 
many cases prevented completely. Some 80% of type 2 diabetes is 
preventable by improving the living environment. This includes dietary 
changes and increased physical activity. Type 1 diabetes (insulin dependent) 
however is not preventable. It predominantly affects youth and is rising 
alarmingly worldwide at a rate of 3% per year.  
Reversing the current trend is not just a health issue. It will require a 
whole-of-government approach and the attention of the international 
community. A United Nations Resolution on diabetes will recognise the 
global burden of diabetes and focus world attention on the need for 
immediate action. IDF hopes that a UN Resolution on diabetes will prompt 
decision-makers to take preventive actions against the growing health 
challenge. 
There is now extensive evidence on the optimal management of 
diabetes, offering the opportunity of improving the immediate and long-term 
quality of life of those with the condition. Unfortunately such optimal 
management is not reaching many, perhaps the majority, of the people who 
could benefit. Reasons include the size and complexity of the evidence-base, 
and the complexity of diabetes care itself. One result is a lack of proven 
cost-effective resources for diabetes care. Another result is diversity of 
standards of clinical practice.  
Guidelines are one part of a process that seeks to address those 
problems. Many guidelines have appeared internationally, nationally, and 
more locally in recent years, but most of these have not used the rigorous 
new guideline methodologies for identification and analysis of the evidence. 
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A global guideline presents a unique challenge. Many national 
guidelines address one group of people with diabetes in the context of one 
health-care system, with one level of national and health-care resources. 
This is not true in the global context where, although every health-care 
system seems to be short of resources, and the funding and expertise 
available for health-care vary widely between countries and even between 
localities. 
Published national guidelines come from relatively resource-rich 
countries, and may be of limited practical use in less well resourced 
countries. 
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APPENDIX II (TABLES) 
 
Table 1.  Prevalence of diabetes in the WHO African region 
Country  2000  2030  
Algeria  426,000  1,203,000  
Angola  51,000  140,000  
Benin  87,000  266,000  
Botswana  25,000  45,000  
Burkina Faso  124,000  388,000  
Burundi  26,000  72,000  
Cameroon  70,000  171,000  
Cape Verde  7,000  24,000  
Central African Republic  18,000  38,000  
Chad  97,000  269,000  
Comoros  4,000  15,000  
Congo  14,000  39,000  
Côte d'Ivoire  264,000  636,000  
Democratic Republic of the Congo  291,000  910,000  
Equatorial Guinea  8,000  21,000  
Eritrea  47,000  142,000  
Ethiopia  796,000  1,820,000  
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Gabon  8,000  14,000  
Gambia  22,000  61,000  
Ghana  302,000  851,000  
Guinea  34,000  89,000  
Guinea-Bissau  17,000  44,000  
Kenya  183,000  498,000  
Lesotho  31,000  42,000  
Liberia  40,000  154,000  
Madagascar  100,000  301,000  
Malawi  55,000  118,000  
Mali  140,000  405,000  
Mauritania  34,000  103,000  
Mauritius  111,000  233,000  
Mozambique  133,000  273,000  
Namibia  25,000  60,000  
Niger  108,000  382,000  
Nigeria  1,707,000  4,835,000  
Rwanda  30,000  77,000  
Sao Tome-Principe  1,000  2,000  
Senegal  143,000  421,000  
Seychelles  8,000  19,000  
Sierra Leone  65,000  178,000  
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South Africa  814,000  1,286,000  
Swaziland  13,000  21,000  
Togo  64,000  184,000  
Uganda  98,000  328,000  
United Republic of Tanzania  201,000  605,000  
Zambia  70,000  186,000  
Zimbabwe  108,000  265,000  
Total  7,020,000  18,234,000 
Resource: http://www.who.int/diabetes/facts/world_figures/en/index.html. 
 
 
 In Nigeria prevalence is estimated to be increased by 65% 
 In South Africa prevalence is estimated to be increased by 47% 
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Table 2.  Prevalence of diabetes in the WHO region of the Americas 
Country  2000  2030  
Antigua and Barbuda  3,000  5,000  
Argentina  1,426,000  2,457,000  
Bahamas  12,000  26,000  
Barbados  11,000  22,000  
Belize  5,000  15,000  
Bolivia  207,000  562,000  
Brazil  4,553,000  11,305,000  
Canada  2,006,000  3,543,000  
Chile  495,000  1,047,000  
Colombia  883,000  2,425,000  
Costa Rica  76,000  237,000  
Cuba  480,000  855,000  
Dominica  3,000  4,000  
Dominican Republic  245,000  594,000  
Ecuador  341,000  921,000  
El Salvador  103,000  320,000  
Grenada  4,000  7,000  
Guatemala  139,000  447,000  
Guyana  19,000  36,000  
Haiti  161,000  401,000  
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Honduras  81,000  269,000  
Jamaica  81,000  189,000  
Mexico  2,179,000  6,130,000  
Nicaragua  68,000  246,000  
Panama  59,000  155,000  
Paraguay  102,000  324,000  
Peru  754,000  1,961,000  
Saint Kitts and Nevis  2,000  2,000  
Saint Lucia  5,000  11,000  
Saint Vincent and the Grenadines  5,000  9,000  
Suriname  9,000  20,000  
Trinidad and Tobago  60,000  125,000  
United States of America  17,702,000  30,312,000  
Uruguay  154,000  224,000  
Venezuela  583,000  1,606,000  
Total  33,016,000  66,812,000  
Resource: http://www.who.int/diabetes/facts/world_figures/en/index.html. 
 
 
 In Mexico prevalence is estimated to be increased by 65% 
 In Canada prevalence is estimated to be increased by 43% 
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 In USA prevalence is estimated to be increased by 41% 
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Table 3.  Prevalence of diabetes in the WHO South-East Asia region 
Country  2000  2030  
Bangladesh  3,196,000  11,140,000  
Bhutan  35,000  109,000  
Dem. People's Rep. of Korea  367,000  635,000  
India  31,705,000  79,441,000  
Indonesia  8,426,000  21,257,000  
Maldives  6,000  25,000  
Myanmar  543,000  1,330,000  
Nepal  436,000  1,328,000  
Sri Lanka  653,000  1,537,000  
Thailand  1,536,000  2,739,000  
Total  46,903,000  119,541,000  
Resource: http://www.who.int/diabetes/facts/world_figures/en/index.html. 
 
 In India prevalence is estimated to be increased by 60% 
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Table 4.  Prevalence of diabetes in the WHO Western Pacific region 
Country  2000  2030  
Australia  941,000  1,673,000  
Brunei Darussalam  18,000  49,000  
Cambodia  110,000  317,000  
China  20,757,000  42,321,000  
Cook Islands  700  1,300  
Fiji  37,000  72,000  
Japan  6,765,000  8,914,000  
Kiribati  4,000  7,000  
Lao People's Dem. Rep.  46,000  128,000  
Malaysia  942,000  2,479,000  
Marshall Islands  2,000  4,000  
Federated States of Micronesia  5,000  13,000  
Mongolia  34,000  81,000  
Nauru  2,000  4,000  
New Zealand  179,000  307,000  
Niue  <100  <100  
Palau  1,000  2,000  
Papua New Guinea  152,000  392,000  
Philippines  2,770,000  7,798,000  
Republic of Korea  1,859,000  3,378,000  
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Samoa  4,000  7,000  
Singapore  328,000  695,000  
Solomon Islands  13,000  41,000  
Tonga  3,000  6,000  
Tuvalu  300  800  
Vanuatu  6,000  17,000  
Viet Nam  792,000  2,343,000  
Total  35,771,000  71,050,100  
Resource: http://www.who.int/diabetes/facts/world_figures/en/index.html. 
 
 In China prevalence is estimated to be increased by 51% 
 In Australia prevalence is estimated to be increased by 44% 
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ABBREVIATIONS 
 
ACE             Angiotensin Converting Enzyme 
ADA            American Diabetes Association 
BMI             Body Mass Index 
CDA            Cyprus Diabetic Association 
CDC            Centres for Disease Control and Prevention 
CVD            Cardiovascular disease 
EASD          European Association for Study of Diabetes 
ECG             Electrocardiogram 
FDA             Food and Drug Administration 
GDP             Gross Domestic Product 
GFR             Glomerular Filtration Rate 
GI                 Gastrointestinal 
GP                General Practitioner 
HbA1c          glycosylated hemoglobin 
HCF              High Carbohydrate high plant-fibre 
HDL              High Density Lipoprotein 
IDDM            Insulin Dependent Diabetes mellitus 
IDF                International Diabetes Federation 
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IFG                Impaired Fasting Glucose 
IGT                Impaired Glucose Tolerance 
IPAQ              International Physical Activity Questionnaire 
IV                   Intravenous 
LDL                Low Density Lipoprotein 
NCHS             National Centre for Health Statistics 
NDP                National Diabetes Programme 
NDRs              National Diabetes Registers 
NHANES        National Health and Nutrition Examination Survey 
NHIS               National Health Interview Survey 
NICE               National Institute for Health and Clinical Excellence 
NIDDM           Non-insulin Dependent Diabetes Mellitus 
NPH                 Isophane insulin 
OGTT              Oral Glucose Tolerance Test 
SIGN                Scottish Intercollegiate Guidelines Network 
TID                   Three times per day 
VLDL               Very Low Density Lipoprotein 
WHO                 World Health Organization 
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ABSTRACT 
 
 My topic was about diabetes mellitus in Cyprus in relation with the 
world. For my diploma work I used literature searches in electronic form 
from different databases and also books, journals, and published articles. 
 My diploma thesis was divided into two main parts, the theoretical 
part and the results. 
 In the theoretical part diabetes mellitus was described according its 
definition, classification, clinical manifestations, complications, diagnosis, 
non-pharmacological and pharmacological treatment. 
 In the results first were described evidence-based guidelines and 
recommendations from NICE for the management, non-pharmacological and 
pharmacological treatment for type 1 and type 2 diabetes mellitus in children 
and adults.  
 Then the general situation of diabetes was described for Cyprus, EU, 
Czech Republic and the world, according the incidence/prevalence of 
diabetes, cost of diabetes care, government priorities, policy framework, 
guidelines and reimbursement. 
 From the results it‟s obvious that the burden of diabetes is constantly 
increasing and immediate measures must be taken to prevent further 
increase. Also it exists the problem with reimbursement for the therapy of 
diabetes in many countries, including Cyprus. 
 Cyprus Diabetic Association (CDA) provides great help for the 
patients with diabetes, especially children, and their families. Among 
activities of CDA are the Diabetes care, child‟s annual review, emotional 
support, help provided from several magazines that CDA is publishing. 
 Most of EU member states have developed national plans against 
diabetes, eg. Czech Republic, but EU has still leading role to play in shaping 
policy and action to encourage member states to provide adequate 
prevention, diagnosis and control of diabetes. 
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